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1. Abstract 
Peptide Nucleic Acid (PNA) has shown great potential in molecular diagnostics, 
antisense/antigene therapy and nanotechnology. Like other synthetic nucleic acids and 
artificial analogues, PNA has been extensively modified to achieve better performance in 
these applications. To efficiently develop PNA probes for molecular diagnosis, this thesis 
is focused on versatile functionalization of PNA via post-synthetic click chemistry.  
Chapter 2 presents the synthesis of quencher-free PNA molecular beacons (MBs) targeting 
a cystic fibrosis transmembrane conductance regulator (CFTR) sequence mutation. To 
avoid the tedious synthesis of functionalized PNA monomers for probe development, a 
simple approach to modify PNA oligomers by post-synthetic on-resin click chemistry was 
developed. Precursor PNA MBs were prepared by incorporation of an Fmoc azide 
monomer into the oligomer by automatic solid-phase peptide synthesis and subsequent 
derivatization with pyrene moieties by copper-catalyzed azide-alkyne cycloaddition 
(CuAAC) produced the functional MBs. Two pyrene-based quencher-free PNA molecular 
beacons, a stemless MB and one possessing a stem-loop structure, both targeting a portion 
of the cystic fibrosis gene, were successfully synthesized by this method. Fluorescence 
studies showed that the stem-loop MB exhibited better discrimination of changes in 
excimer/monomer ratios as compared to the stemless MB construct and showed promise 
as MB for detection of this CFTR mutation. 
Chapter 3 reports the synthesis of PNA MBs targeting CFTR mutation via a “click-couple-
click” method. Unlike the well-known synthetic procedure of conventional PNA MBs that 
requires different protection strategies on the sites where fluorophores and quenchers are 
attached, an on-resin “click-couple-click” approach that includes microwave-assisted on-
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resin CuAAC of a quencher to PNA, coupling of an azide-containing PNA monomer and 
another on-resin CuAAC of a fluorophore without the need of protection. By using this 
method, various PNA MBs have been successfully synthesized and characterized. 
Chapter 4 discloses the simultaneous, multiple conjugations of alkynyl-(Gd(III)-DOTA) to 
a PNA oligomer possessing azide residues in a single post-synthetic CuAAC reaction. The 
resulting probe, (Gd(III)-DOTA)4-PNA, has potential as a MRI contrast agent. 
Conceptually by binding to the target, poly(rA) tail of mRNA, Gd ions would be 
significantly loaded to a localized microenvironment, which may improve the 
enhancement of contrast in MR images. The in vitro MR characteristics of this probe is 
presented. 
With the interest in the conjugation of gold nanoparticles (AuNPs) to PNA for the 
development of targeted contrast agents for CT imaging, preliminary studies have been 
carried out by conjugation of an oligopeptide to AuNPs. Chapter 5 introduces a new 
method combining an interfacial strain-promoted azide-alkyne cycloaddition and post 
assembly deprotection (SPAAC-PAD) for the well-defined functionalization of small, 
water-soluble gold nanoparticles with oligopeptides. This approach will enable the 
fabrication of gold nanoparticles with a high degree of complexity with biomolecules for a 
variety of applications in targeted cancer diagnosis and therapies.  
Keywords 
Peptide Nucleic Acids, click chemistry, on-resin, molecular beacon, post-synthetic 
modification, magnetic resonance imaging, contrast agent, poly(rA) tail, gold 
nanoparticles, peptide.  
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10. CHAPTER I: INTRODUCTION 
 
1.1 Preface 
The year 2016 witnessed the 25th anniversary of the disclosure of Peptide Nucleic Acid 
(PNA). Since the first publication in 1991, PNA has been intensively researched and 
extensively exploited due to its unique properties especially in regard to the high nucleic 
acid recognition specificity and affinity in binding to complementary sequences. Great 
advances in employing PNA for a wide variety of applications in the field of medical 
diagnostics, drug discovery, molecular biology and nanotechnology have been made.  
1.2 Peptide Nucleic Acid 
PNA, an artificial nucleic acid analogue in which the entire sugar phosphate backbone 
found in natural nucleic acids, has been replaced with N-(2-aminoethyl)glycine (aeg) units 
and was first described by Nielsen et al. in 1991 (Figure 1.1).1 PNA was originally 
conceived as a sequence-specific binding reagent targeting the major groove of duplex 
DNA to form a triplex. The nucleobases (purines and pyrimidines) are joined to the 
backbone by methylene carbonyl linkages. The intramolecular distances and the identity 
of the nucleobases are like those in natural nucleic acid molecules. More importantly, 
specific hybridization occurs between PNA and DNA or RNA sequences obeying Watson-
Crick base pairing rules. The neutral polyamide backbone of PNA leads to binding 
complementary nucleic acid strands with higher affinity whereas electrostatic repulsions 
occur between the negative phosphate groups on each strand of DNA. Additionally, PNA 
hybridizes to DNA or RNA sequences under low salt conditions while cations are needed 
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to counteract the inter-strand repulsion between two negatively charged natural nucleic 
acid strands which would hamper duplex formation. Although DNA may depurinate under 
acidic conditions, PNA is more stable across a wide range of temperatures and pH values.2 
It is also resistant to nucleases and proteases unlike natural nucleic acids.3 All these unique 
properties have made PNA advantageous hybridization probes in various applications. 
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Figure 1.1 Chemical structures of double-stranded DNA and PNA. 
1.3 Synthesis of PNA  
The preparation of PNA oligomers is based on standard solid phase peptide synthesis 
(SPPS) protocols developed by Merrifield,4 after which two different protection schemes: 
tert-butyloxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc), have been 
employed. Although Boc chemistry of PNA has been well developed, the detracting 
qualities cannot be neglected such as the repeated use of extremely hazardous and corrosive 
TFA that effectively prevents non-chemists from accessing PNA and makes synthesis 
onerous. Alternatively, Fmoc-based PNA synthesis has milder deprotection/cleavage 
procedure allows for a wider range of labeled molecules to be prepared and provides for 
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simplified final cleavage and deprotection in shorter time. Therefore, Fmoc-based SPPS 
has become the most popular synthetic strategy of PNA synthesis. 
1.3.1 Fmoc-based SPPS 
To apply Fmoc-based SPPS, the protecting group on nucleobases not only needs to be 
compatible with Fmoc group, but also needs to be removed readily under cleavage 
conditions and render solubility to the resulting monomers. The benzhydryloxycarbonyl 
group (Bhoc) has been identified as an appropriate candidate. It allows the PNA monomers 
to be maintained at 0.2 M in NMP for weeks and it is completely removed in less than 1 
minute in neat TFA, which is convenient for cleavage. Fmoc/Bhoc PNA monomers are 
commercially available (Figure 1.2). 
 
Figure 1.2 Standard Fmoc/Bhoc PNA constructs for SPPS. 
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Fmoc-based SPPS consists of repetitive cycles of deprotection, activation-coupling, 
capping as well as cleavage and deprotection (Scheme 1.1). Fmoc-based SPPS of PNA is 
usually performed on a peptide synthesizer such as Applied Biosystems ABI-433A (Figure 
1.3). 
 
Scheme 1.1 Fmoc-based PNA synthesis cycle. 
 
Figure 1.3 Automatic peptide synthesizer [Applied Biosystems ABI-433A]. 
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The deprotection step of PNA synthesis represents the removal of Fmoc group from the 
primary amine of the PNA backbone. It liberates the amine for subsequent coupling of 
monomers. Generally, a solution of 20% piperidine in DMF is used for this purpose to 
decompose Fmoc group to dibenzofulvene (DBF).  
In the coupling step, monomer, base and activator are all required. A solution containing 
0.2 M DIPEA and 0.3 M lutidine has been used which proved more effective than 0.5 M 
of either base alone in terms of observed side reactions and coupling yields.5 O-
(Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) or 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) are preferred as the activator for the coupling reaction. The 
step of combining solutions of monomer, base as well as activator followed by activation 
before exposure to the solid support is challenging on oligonucleotide synthesis platforms. 
Therefore, peptide synthesizer which has the same procedure is generally ideal for PNA 
synthesis. 
The acetylation of oligomer that failed to extend is performed post coupling during each 
cycle of the stepwise synthesis. Capping simplifies the purification of the full length PNA 
which is highly recommended but not strictly necessary. Capping solution containing 5% 
acetic anhydride and 6% lutidine in DMF has been demonstrated a longer shelf life (months 
to years) than acetic anhydride and bases such as DIPEA or pyridine in DMF.  
PNA may be deprotected and cleaved from the solid support simultaneously by treatment 
with TFA/TES (95/5). The use of a scavenger is necessary because the electron rich 
aromatic rings of the nucleobases will be alkylated by cations generated by the TFA 
treatment. The removal of Bhoc protection is complete within 1 minute, releasing the 
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exocyclic amines of the nucleobases and producing benzhydryl cations, which would be 
effectively scavenged by TES. PNA is also cleaved from the solid support with TFA 
treatment at the same time and the resulting oligomer is isolated from cleavage mixture by 
precipitation with diethyl ether.  
Resins for SPPS can generally be used for PNA synthesis. The resin consists of three parts: 
base material, linker and anchoring group (Figure 1.4). Various types of resins have been 
widely employed depending on base materials: the classic polystyrene (PS) resins, 
polyamine resins and TentaGelTM resins which contain polyethylene glycol (PEG) attached 
to PS.  
 
Figure 1.4 The composition of resin for SPPS. 
Most of the resins are commercially available attached with a variety of different linkers. 
Examples of resins with linkers and anchoring groups for SPPS have been shown in Figure 
1.5 including Merrifield resin and Wang resin for synthesis of peptide acids, 2-chlorotrityl 
chloride resin for synthesis of protected peptide acid, rink amide resin for synthesis of 
peptide amide.  
Cl
Merrifield resin
O
HO
Wang resin
Cl
Cl
2-chlorotrityl chloride resin
O
H2N
MeO
MeO
rink amide resin
 
Figure 1.5 Examples of resins for SPPS. 
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Different protocols are required to preload the first monomer to the resins depending on 
the anchoring groups. PNA synthesis is optimally performed on resins loaded below 0.2 
mmol/g, because PNA quality would be compromised at higher loading due to aggregation 
of the extending oligomer during synthesis. Therefore, it is usually necessary to download 
the resin before PNA synthesis. 
1.4 Chemical modification of the PNA 
1.4.1 Nucleobases modifications in PNA 
The formation of stable duplex and triplex structures is of great significance in most 
applications of PNA. In this context, the modification of nucleobase of PNA monomer is 
an effective way to control recognition between nucleic acids strands. Nucleobase 
modification of PNA has been comprehensively reviewed by Hudson and coworkers.6 For 
example, 5-bromouracil (5-BrU) and 5-methylcytosine (5-MeC) have been found to increase 
the stability of both double and triple helices in DNA (Figure 1.6). Furthermore, a common 
method for the derivatization of pyrimidine bases, especially uracil, is to take advantage of 
transition metal-catalyzed cross-coupling between the halogenated nucleobase and 
terminal alkynes using the Castro-Stephens/Sonogashira reaction. Various alkynes could 
be used to introduce tethered functional groups. The synthesis of a variety of 5-
alkynyluracil monomers that are compatible with Boc-based oligomerization chemistry has 
been developed. (Figure 1.6)7 However, the incorporation of the 5-alkynyl group only 
produced very modest stabilization, as all PNA-DNA chimeras formed complexes of lower 
stability than the control DNA:DNA duplex. 
8 
 
 
Figure 1.6 5-Modified pyrimidines. 5-BrU: 5-bromouracil; 5-IU: 5-iodouracil; 5-MeC: 5-
methylcytosine; 5-PAU: 5-(propargyl alcohol)uracil; 1: 5-(p-methoxy-
benzylthiopropargyl ether)uracil; 2: 5-(N-(4,5-dimethoxy-2-
nitrobenzylprogargylcarbamate)uracil; 3: 5-(ferrocenylpropargylcarboxamide)uracil. 
To enhance the stability of complexes formed by PNA and target DNA/RNA, nucleobases 
with a larger π-surface area for stronger stacking interactions or that are able to make 
additional H-bonds or that are positively charged have been prepared (Figure 1.7). A series 
of bicyclic thymine analogs (bT) based on the 1,8-napthyridin-2-(1H)-one ring system has 
been prepared and evaluated by Nielsen and coworkers (Figure 1.7).8,9 The best 
performance in terms of stabilization of duplexes and triplexes was 7-chloro-1,8-
napthyridin-2(1H)-one (7-Cl-bT). Tricyclic analogs of cytosine have shown better 
performance in oligonucleotide chemistry. A tricyclic cytosine analog (tC) has been 
reported by Nielsen and coworkers which performs well to be stabilizing in duplex-forming 
sequences, especially in contiguous positions or adjacent to purines. The phenoxazine 
cytosine analog was used to scaffold a tethered amine that could provide an additional H-
bond to its complement. However, it was found to give no or minor stabilization depending 
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on the target. The G-clamp was prepared in order to build in specific, additional bonding 
interactions. The G-clamp and propyl-G-clamp led to stabilization while maintaining 
excellent sequence discrimination.10 Fmoc/Cbz-protected monomers of the G-clamp and 
guanidine G-clamp derivatives have been developed.11 Additionally, Nielson and 
coworkers have attempted to retain the benzoyl group (Bz) on the exocyclic amine of 
cytosine. The monomer, N4-benzoylcytosine (CBz) is compatible with Boc-oligomerization 
chemistry. The incorporation of CBz into poly-pyrimidine PNA sequences would normally 
strongly favor triplex formation. 
 
Figure 1.7 Analogues of thymine and cytosine. 
1.4.2 Modification of PNA on the backbone 
PNA analogues with a modified backbone have also drawn scientists’ attention. The 
repeating backbone unit has been extended with a methylene group to either N-(2-
aminoethyl)-alanine or N-(3-aminopropyl)glycine or propanoic acid unit with the ethylene 
carbonyl linker (4, 5, Figure 1.8).12 However, minor importance for the stability of PNA 
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has been observed when an extra methylene group is placed in the backbone. Hyrup et. al. 
reported a more flexible backbone containing a secondary amine replacing the secondary 
amide (PANA) (6, Figure 1.8).13 After coupling of the nucleobase, the double bond of 
secondary amide is oxidised to aldehyde. The PANA oligomer is then obtained on solid-
phase by reductive amination. Surprisingly, the incorporation of one PANA monomer does 
not destabilize the duplex, either. 
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Figure 1.8 Some examples of backbone modified PNA monomers.  
To overcome the poor solubility issue of PNA in aqueous environment, PNAs with a 
constrained trans-4-hydroxy-N-acetylpyrrolidine-2-phosphonate backbone (pHypNAs) 
were introduced. (7, Figure 1.8)14 It has been revealed that they have excellent solubility 
in water and at the same time preserve biological stability and high hybridization 
characteristics of classical PNAs.15,16 These PNA also showed good ability to penetrate cell 
membranes together with high antisense activity in a cell-free system, in living cells and in 
model organism.  
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Oxy-PNA (OPNA) with an ether linkage in the main chain was reported by Kuwahara in 
1999. OPNA is chiral with nucleobases attached to the backbone via an ethylene linker.17 
8, Figure 1.8) The ether linkage of the backbone improves the solubility of the oligomers 
in water. Other chiral PNAs (CPNAs) with modification on the backbone have also been 
obtained by incorporation of substituents at either the α- or the γ-position. Comparison of 
the effects of substituents at the α-position with those of the γ-position revealed that γ-
modification is more effective to improve the DNA binding ability.18 Also, PNA monomers 
with a methyl group at the β-position have been synthesized.19 
Additionally, the attempts of rigidifying the backbone of PNAs have been made avoid the 
problem of rotamers that exist around the tertiary amide bond in regular aeg PNAs, thus 
obtaining high selectivity in the binding of DNA/RNA (Figure 1.9).  For example, 
aminoprolyl (ap), aminoethylprolyl (aep), aminoethylpyrrolidinone (aepone) and 
pyrrolidine PNAs have been all synthesized from the same scaffold 4-hydroxyproline. 
Cyclopropane (cpr) PNA carries a very rigid 3-member ring. Introduction of methylene 
bridging β-C and γ-C of the aminoethyl moiety as in cyclopentyl (cp) and cyclohexyl (ch) 
PNAs results in stabilization of DNA and RNA duplexes. 
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Figure 1.9 Structures of conformationally rigid PNAs, stereochemistry not shown. 
1.4.3 Modification of PNA on the nucleobase-backbone linker 
Besides nucleobase modified PNAs and backbone modified PNAs, many linkage-modified 
PNA analogues have also been synthesized. For example, the linker to the nucleobase was 
extended from methylenecarbonyl to ethylenecarbonyl.12 The thermal stability of the 
hybrids between these PNA oligomers and complementary DNA oligonucleotides was 
significantly lower than that of the corresponding complexes involving unmodified PNA. 
Therefore, the distance between the backbone and the nucleobases plays a major role in the 
stability of PNA-DNA hybrids. However, the sequence selectivity was retained.  
To understand the role of the nucleobase-backbone linker in the PNA oligomer structure 
and in the hybridization process, molecules lacking the tertiary amide bond between the 
base and the backbone were synthesised. It has been investigated that the methylene 
carbonyl unit was replaced by a flexible ethylene linker (Figure 1.10).20 The amide 
functionality in the base-linker unit in PNAs has been found to determine significantly the 
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affinity and preferred strand orientation in PNA/DNA duplexes. Nevertheless, OPA offers 
the unique possibility to introduce a fourth substituent on the double bond, which could be 
of interest for improving binding or solubility properties, or for the attachment of functional 
units that may act on bound complementary RNA or DNA.  
 
 
Figure 1.10 Sections of the chemical structures of deoxyribonucleic acids (DNAs), 
polyamide or peptide nucleic acids (PNAs), and (E)- and (Z)-olefinic polyamide nucleic 
acids (OPAs)20 (copyright 2000 John Wiley and Sons). 
1.4.4 Post-synthetic modification of PNAs and click chemistry 
A vast number of modified PNA monomers have been reported to be compatible with 
Boc/Fmoc chemistry. However, individual modification of nucleobases in PNA monomers 
is always time-consuming and labour intensive. Therefore, post-synthetic functionalization 
of the PNA oligomer represents a viable alternative to potentially reduce the overall 
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synthetic effort, as well as introducing a step that is amenable to structural diversification 
is attractive. In 2001, Ikeda and co-workers synthesized an amino-containing PNA 
monomer and successfully functionalized a PNA oligomer through a post-synthetic amide 
bond formation.21 Later the Hudson group prepared a PNA monomer containing the methyl 
orotate nucleobase which is compatible with Fmoc-based synthesis. Treatment of the resin-
bound oligomers with hydroxide or amines cleanly converted the ester to an orotic acid or 
orotamide-containing PNA.22 Additionally, Seitz reported the introduction of Boc-
protected N6-aminoalkyladenine into PNA oligomer. After the removal of the Boc-group, 
a fluorescent reporter was post-synthetically attached to the N6-position of adenine.23 More 
recently, PNA monomers with an alkynyl or azido group have been developed with the aid 
of click chemistry.24,25 
Click chemistry was first described by Sharpless and coworkers in 2001.26 It refers to 
reactions those are fast and easy to perform, give rise to the intended products in very high 
yields with little or no byproducts, work well under many conditions, and are unaffected 
by the nature of the groups being connected to each other. A series of click reactions have 
been discovered and employed that include copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC), strain-promoted azide-alkyne cycloaddition (SPAAC), strain-promoted alkyne-
nitrone cycloaddition (SPANC), alkene and azide [3+2] cycloaddition, alkene and tetrazine 
inverse-demand Diels-Alder as well as alkene and tetrazole photoclick reaction. Before 
long a tremendous number of applications using click reactions emerged among diverse 
research areas including nucleic acids, drug discovery, material sciences and 
nanotechnology. 
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Obviously, click chemistry is also an attractive strategy for modifications of PNA 
monomers and/or bioconjugation of oligomers. Kumar and co-workers have reported the 
synthesis of peptide-oligonucleotide conjugates by using CuAAC.27 An alkyne-containing 
PNA monomer for the facile insertion of one or two organometallic ferrocenyl moieties 
into PNA oligomers via CuAAC was reported by Metzler-Nolte and co-workers (9, Figure 
1.11).24  Later the same group described the facile N-terminal functionalization of PNA 
with azide or alkyne functionalities on the solid phase, and their subsequent conversion by 
click chemistry with different alkynyl and azido ferrocene derivatives to yield a small 
library of ferrocene-PNA bioconjugates.28 Additionally, two clickable PNA monomers 
were reported by Winssinger et al. (10, 11a, 11b, Figure 1.11). PNA fragments may be 
assembled by using these monomers via CuAAC. N-propargyl analogues (12a-c, Figure 
1.11) were synthesized and used to synthesize PNAs bearing a triazole in lieu of the amide 
bond assembled using a “click” cycloaddition.29 An efficient, versatile PNA ligation 
method using click chemistry was demonstrated for quantitative conjugation of PNA with 
DNA, PNA, or peptide under mild conditions (Figure 1.12).30  
 
Figure 1.11 PNA monomers for click chemistry. 
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Figure 1.12 Template-directed click-ligation of PNA-DNA, PNA-PNA (or peptide): (a) 
schematic structure and (b) chemical structure at ligation point30 (copyright 2010 John 
Wiley and Sons). 
More recently Manicardi et al. reported an Fmoc PNA monomer bearing 5-
azidomethyluracil nucleobase.31 The azide group could be reduced to amine, which was 
then coupled with naphthalene-2-carboxylic acid. The azide functional group was also 
exploited as reactive tool for the modification of PNA in solution via CuAAC. Similarly, 
an azide-containing acpcPNA monomer was synthesized (14, Figure 1.11) and 
modification of D-prolyl-2-aminocyclopentane carboxylic acid backbone (acpcPNA) via 
CuAAC was investigated.32 Pyrene units could be pre-clicked to the azido acpcPNA 
monomer or be post-synthetically attached to PNA oligomers via click reaction. The same 
group also reported an approach for th
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e site-specific attachment of fluorophores to the backbone of acpcPNA via reductive 
alkylation and sequential reductive alkylation-click chemistry (Figure 1.13).33 Besides, to 
explore the potential for utilization of clickable PNAs, Hudson group reported the synthesis 
of an azide containing PNA monomer.25 The azide group could be used as a tool for on-
resin copper catalyzed azide-alkyne Huisgen cycloaddition (CuAAC). At the same time, a 
simple approach to modify PNA oligomers by post-synthetic on-resin click chemistry was 
described later by us.34 In this way, modification of more than one position of a PNA 
oligomer could be performed in a single step and lends itself to divergent syntheses of 
modified PNAs. Furthermore, Cγ-substituted azido PNA monomers were synthesized and 
inserted into PNA oligomers at specific sites followed by click reaction with propyne 
carboxyfluorescein (Figure 1.14).35 The resulting oligomers have been seen by live cell 
imaging to accumulate around the nuclear membrane in 3T3 cells.  
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Figure 1.13 Illustration of site-specific attachment of fluorophores to the backbone of 
acpcPNA via reductive alkylation and sequential reductive alkylation-click chemistry33 
(copyright 2013 American Chemical Society). 
 
Figure 1.14 Illustration of click reaction of Cγ-azido PNA monomer with fluorophore and 
live cell imaging of the fluorescent oligomers35 (copyright 2014 American Chemical 
Society). 
Therefore, upon the progress of functionalization of PNAs, success has also been achieved 
on the application of click chemistry in the modification of nucleobase, backbone as well 
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as linker of PNA. This facile, convenient method has significantly pushed forward the 
development of useful targeted PNAs. 
1.5 Applications of PNA 
As PNA is a powerful molecular tool due to it unique properties and chemistry, extensive 
applications have been investigated by using PNA.36–38 Most applications of PNA are 
focused on the detection of specific nucleic acids by hybridization,39,40 which has been 
widely utilized for gene-related research. It has been demonstrated that PNA is of great use 
for developing diagnostic devices, gene detection and therapeutic agents, and nucleic acid 
manipulations. In vitro studies indicate that PNAs could inhibit both transcription and 
translation of genes to which they have been targeted, thus holding promise for their use 
for antigene and antisense therapy.  
1.5.1 PNA beacons and fluoroprobes 
Molecular beacon (MB) is a single-stranded oligonucleotide molecule containing a stem-
loop structure labeled with a fluorophore (F) and a quencher (Q) on each end (Figure 
1.15).41 It is a powerful probe for selectively detecting DNA and RNA targets. As shown 
in Figure 1.15, these probes undergo “off-on” switch with a spontaneous fluorogenic 
conformational change when they hybridize to their targets. In addition to the standard 
DNA beacon design, a number of PNA beacons have been reported due to the superior 
properties of PNA. The application of PNA will be further discussed in chapter II.  
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Figure 1.15 Schematic representation of molecular beacon42 (copyright 2006 Nature 
Publishing Group). 
1.5.2 Single nucleotide polymorphisms (SNPs) detection using PNA 
Single Nucleotide Polymorphisms (SNPs) are one of the major sources of genetic variation 
in human genome. Numerous diseases such as cystic fibrosis, thalassemia and Alzheimer’s 
disease are related to SNPs. The use of PNAs for detections of SNPs has been proved to 
be one of the most sensitive approach depending on PNA’s unique hybridization properties 
and its great ability to distinguish mismatches of bases.52 Petersen et al. reported a real-
time PCR assay for the genotyping of SNPs using short PNA molecular beacons.43 A 
method has been described by Ren and coworkers which straightforwardly genotypes SNPs 
in dsDNA by matrix-assisted laser desorption/ionization time-of-fight mass spectrometry 
(MALDI-TOF MS) in the presence of PNA.44 Rockenbauer et al. demonstrated a simple, 
rapid, and robust approach for solid-phase SNP genotyping that combines allele-specific 
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hybridization, PNA technology, and flow cytometric detection.45 A strategy employing a 
combination of PNA probes, an optically amplifying conjugated polymer (CP), and S1 
nuclease enzyme has shown the capability of detecting SNPs in a simple, rapid, and 
sensitive manner.46 Bethge et al. reported forced intercalation probes (FIT-probes) in which 
an intercalator cyanine dye such as thiazole orange (TO), oxazole yellow (YO), 
thiazolopyridine (MO), and oxazolopyridine (JO) serves as a replacement of a canonical 
nucleobase. These FIT-probes have shown potential for detection of SNPs (Figure 1.16).47 
Interestingly, an electrochemical biosensor has also been developed for the detection of 
SNPs using PNA probes. It takes advantage of the significant structural and 
physicochemical differences between the full hybrids and SNPs in PNA/DNA and 
DNA/DNA duplexes. Ferrocene-conjugated chitosan nanoparticles (Chi-Fc) were used as 
the electroactive indicator of hybridization.48 Additionally, a new PNA biosensor has been 
reported for electrochemical detection of point mutation in p53 gene corresponding 
oligonucleotide based on PNA:double-stranded (ds) DNA triplex formation.49 
 
Figure 1.16 Design principle of FIT-probes. An intercalator fluorophore (F) serves as a 
base surrogate and is forced to intercalate adjacent to the expected mutation site. High 
fluorescence is only obtained upon formation of matched duplexes47 (copyright 2008 
Elsevier). 
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A reliable PNA microarray-based method for accurately detecting SNP in human genes 
has been described by Mun and coworkers.50 The technique relies on the mismatched 
cleavage activity of a single-strand specific (SSS) nuclease. In order to exploit the superior 
hybridization properties of PNA with target Human papilloma virus (HPV) DNAs, a novel 
PNA array (PANArray HPV) has been developed.51 It enables the detection and genotyping 
of HPVs using 32 type-specific PNA capture probes for medically important HPVs. All 
tested HPV types showed highly unique hybridization patterns with type-specific PNA 
probes. Before long studies were carried out to evaluate PANArrayTM HPV kit for detection 
and genotyping of 19 high-risk and 13 low-risk HPV types, and compare it with the 
commercially available DNA chip kit genotyping of 24 HPVs.52 The PANArrayTM HPV 
test proved to be highly sensitive and accurate even when multiple HPV infections were 
present. Then PANArrayTM HPV kit became a popular, commercially available product, 
which takes advantage of PNA’s unique properties. In this way, the HPV genotyping can 
be completed in a shorter time with smaller DNA samples. In addition, multiple infections 
with several HPV genotypes can be precisely identified for diagnosis. Another advantage 
is its long shelf life even at room temperature because of chemical stability of PNA. 
Tedeschi and coworkers designed and synthesized seven modified PNA probes.53 PNA-
microarrays based on these probes were prepared and applied to SNP discrimination in 
model experiments using oligonucleotide mixtures that simulate the different sequences of 
the seven tomato varieties. Although the efficiency of binding was somewhat lower than 
what is shown by standard PNA arrays, the unsurpassed specificity of the PNA probes still 
makes them very promising for the development of PNA-based genotyping methodologies. 
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1.5.3 PNA and DNA for Fluorescence In Situ Hybridization 
Fluorescence in situ hybridization (FISH) is a cytogenetic technique that uses fluorescent 
probes to bind to only those parts of the chromosome with a high degree of sequence 
complementarity.54 It is an important molecular assay for determining the number, size 
and/or location of specific DNA sequences in mammalian cells, which is developed in the 
combination of the microscopy observation and the specificity hybridization of 
DNA/rRNA.55 Perry-O’Keefe reported a standard FISH method using PNA probes for 
analysis of gram-negative, gram-positive bacteria, as well as yeast. Fluorophore labeled 
PNA probes were designed targeting specific rRNA sequences of Escherichia coli, 
Pseudomonas aeruginosa, Staphyloccocus aureus, Salmonella as well as eubacteria and 
eucarya.56 In addition, a PNA probe (CJE195) was designed and found to bind with higher 
affinity to a previously reported low affinity site on the 16S rRNA than the corresponding 
DNA probe.55 Huang et al. reported a PNA probe for detection of the toxic dinoflagellate, 
Takayama pulchella TPXM, by employing FISH combined with epifluorescent 
microscopy and flow cytometry.57 In 2011, Shiraishi and coworkers developed a pair of 
biotinylated PNA probes targeting two sequences in 18S rRNA from the parasite 
Trypanosoma brucei at a distance of 191 nt (corresponding to maximum distance of ca. 60 
nm) from each other.58 It has been shown that by simple fluorescence microscopy analysis, 
PNA probes specifically detect the presence of 18S rRNA in a total RNA extract from less 
than 300 parasites. Later Zhang et al. reported a PNA-FISH method for detection of 
Listeria species (Figure 1.17).59 In silico analysis showed that three PNA probes Lis-16S-
1, Lm-16S-2 and Liv-16S-5 were capable to specifically identify Listeria genus, Listeria 
monocytogenes and Listeria ivanovii, respectively, in comparison with the control probe. 
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PNA-FISH method has also been applied in identification of probiotic bacteria such as 
Lactobacillus species and Vibrio genus, demonstrated by Machado et al. and Zhang et al., 
respectively. 60,61 To date, PNA FISH tests have been greatly interesting and 
commercially available for rapid identification of bacteria and yeast directly from positive 
blood cultures. They not only enhance the efficiency of hospitals for appropriate therapy 
while avoiding unnecessary use of antibiotic, but also improve patient outcomes as well as 
lower hospital costs.62,63 
 
Figure 1.17 Typical PNA hybridization results. (control, top left) Cells of Vibrio flurialis 
ATCC 33810 hybridized with the universal probe BacUin. (top right) Cells of L. grayi Li07 
hybridized with the Listeria-specific probe Lis-16S-1. (bottom left) Cells of L. 
monocytogenes SLCC2755 hybridized with the L. monocytogenes-specific probe Lm-16S-
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2. (bottom right) Cells of L. ivanovii Li01 hybridized with the L. ivanovii-specific probe 
Liv-16S-5.59 (copyright 2012 Elsevier) 
1.5.4 Antigene and antisense therapy 
Antisense technology is a significant approach to inhibit or down-regulate the production 
of a target protein by using antisense DNA, RNA and artificial DNA/RNA analogues. An 
antisense sequence is an oligonucleotide that is perfectly complementary to the target 
nucleotide sequence present in the cell. There are two possible mechanisms for an antisense 
effect. The one that relies on targeting of the mRNA is called the antisense strategy. The 
other one that is designed to bind to the double-stranded DNA or genes situated in the 
nucleus, is called the antigene strategy (Figure 1.18). Whereas the antisense strategy is well 
established with several examples of in vitro and in vivo applications,64 the antigene 
approach is still in its infancy and the understanding of the involved mechanism is limited.  
 
Figure 1.18 Representation of antisense and antigene strategies.65 (copyright 2002 Royal 
Society of Chemistry) 
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Earlier studies have shown that the binding of PNA to complementary DNA can efficiently 
block transcriptional elongation and inhibit the binding of transcriptional factors. Boffa 
and coworkers demonstrated that PNA could invade the CAG triplets of the androgen 
receptor (AR) and TATA-binding protein (TBP) genes in human prostatic cancer cells. It 
has been shown that the PNAs readily entered the nuclei of lysolecithin-permeabilized cells 
and effectively inhibited sense transcription of unique AR and TBP DNA sequences 
downstream of the site of PNA:DNA hybridization.66 PNA-mediated inhibition of 
transcription was also reported for the alpha-chain of the interleukin-2 receptor.67 Nielsen 
et al. have discussed that even an 8-mer PNA can efficiently block transcription by binding 
to DNA duplex. 68 Therefore, the antisense potential of duplex-forming and triplex-forming 
PNAs has been investigated. 69 It has also been found that PNA interacts with mRNA 
independently of the RNA secondary structure. Studies on the mechanisms of antisense 
activity have demonstrated that PNA inhibits expression in a different way from regular 
antisense DNA/RNA which needs RNase-H mediated degradation of the mRNA-
oligonucleotide hybrid. Because PNA is not recognized by RNase, its antisense effect acts 
through steric interference of either RNA processing (transport into cytoplasm) or 
translation (caused by binding to the mRNA).  
Not surprisingly, the antisense and antigene properties of PNA has been described as early 
as in 1992. 70 It has been shown that PNA or a mixed sequence 15-mer PNA to the 
transcribed strand of a G-free transcription cassette caused 90 to 100 percent site-specific 
termination of pol II transcription elongation. Mologni et al. reported that three different 
regions of the PML/RARα oncogene, including two AUG potential start codons, were 
studied as targets of translation inhibition by antisense PNA in a cell-free system.71 
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Furthermore, the inhibition of gene expression by peptide nucleic acids (PNAs) inside cells 
has also been explored.72 PNA has also been reported to efficiently recognize the RNA 
component of human telomerase (hTR) and inhibit enzyme activity with IC50 values in the 
picomolar to nanomolar range. 73 
An in vivo study has been performed by using PNA to inhibit δ-opioid receptor gene 
function.74 However, the progress using PNA for regulation of gene expression was 
hampered by the poor cellular uptake of “naked” PNA by live cells. Therefore, 
modifications of PNA oligomers were necessary to improve the uptake of PNA in 
eukaryotic living cells. For example, PNA coupled to DNA oligomers, to receptor ligands 
or to cell penetrating peptides (CPPs), could help deliver PNA into cells.75 Among these 
attempts, PNA-CPP conjugates are of great interest since CPPs are rapidly internalized by 
mammalian cells. Pooga et al. reported the use of a PNA-peptide conjugate in the 
downregulation of the galanin receptor in neuronal cells in culture.76 Additionally, cationic 
liposomes have been demonstrated to efficiently complex DNA-PNA hybrid molecules 
which effectively improves the in vivo delivery.77  
As a hybridization probe, PNA has shown its promise in the above-mentioned applications. 
However, the poor cellular uptake and water insolubility of PNA limit its utilization in in 
vivo applications.  
1.6 Overview 
Based on the advantages and development of PNAs, the objective of this research is to 
develop functionalized PNAs that can be used in various applications via post-synthetic 
click chemistry. Chapter II describes the design and synthesis of quencher-free PNA 
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molecular beacons based on solid-phase post-synthetic click chemistry which has been 
demonstrated to be versatile and convenient. The prepared stem-loop PNA beacon showed 
rapid binding and response to target cystic fibrosis gene sequence. 
Chapter III introduces a “click-couple-click” approach for synthesis of conventional PNA 
beacons that contain different reporters on each terminus. The current method for the 
synthesis of PNA MBs is mostly based on amide formation to attach reporters to PNA 
sequences. However, the complicated protection strategies are required to avoid side 
reactions as amide formation possibly happens everywhere in PNA oligomers. In this work 
we develop a new method based on solid-phase microwave-assisted CuAAC, which allows 
fast, convenient preparation of various conventional PNA beacons. One reporter could be 
clicked to an azido-containing PNA first followed by coupling of another azide PNA 
monomer. A different reporter would be clicked to the resulting PNA to yield a PNA MB. 
This method based on “click-couple-click” is chemically selective, robust and efficient.  It 
is also of great use for screening fluorophore and quencher pairs for PNA MBs. 
Chapter IV describes the preparation of a (Gd(III)-DOTA)4-PNA conjugate targeting 
poly(A) tail. On-resin CuAAC has been used to conjugate four units of Gd(III)-DOTA to 
a PNA oligomer that contains 10 thymine PNA monomers. Hybridization with poly(A) tail 
would significantly increase the loading of Gd ions in a microenvironment, thus helping 
enhance the contrast of MRI. 
Chapter V shows the bioconjugation of an oligopeptide to gold nanoparticles via strain-
promoted azide-alkyne cycloaddition via post-assembly deprotection (SPAAC-PAD). This 
strategy would be of great use for functionalization of gold nanoparticles with peptides for 
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targeted CT imaging. The success of this approach also allows for the functionalization of 
AuNPs with PNAs for various applications. 
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11. Chapter II: VERSATILE SYNTHESIS OF QUENCHER-FREE 
PNA MOLECULAR BEACONS VIA POST-SYNTHETIC 
CLICK CHEMISTRY FUNCTIONALIZATION 
Chapter 2 has been published as a research paper, and it is reprinted (adapted) with 
permission from Xiaoxiao Wang, Robert H. E. Hudson*, ChemBioChem, 2015, 16, 2156–
2161. Copyright 2015 John Wiley and Sons. 
2.1 Introduction to PNA-based molecular beacons 
First reported by Tyagi and Kramer in 1996, a molecular beacon (MB) is a single-stranded 
oligonucleotide molecule containing a stem-loop structure labeled with a fluorophore (F) 
and a quencher (Q) on each end.1 MBs are powerful hybridization probes for simple and 
rapid detection of specific DNA/RNA sequences. These probes undergo “off-on” switch 
with a spontaneous fluorogenic conformational change when they hybridize to their targets.  
A typical MB structure consists of a loop, a stem and reporters. The loop is a 18-30 single-
strand region of the MB which is complementary to the target sequence. The stem contains 
two short (4-6 nucleotide residues) oligonucleotides that are complementary to each other 
to maintain the closed hairpin structure. Reporters represent a fluorophore and a quencher. 
Two forms of energy transfer mechanism in MBs have been proposed: dynamic and static 
fluorescence quenching.2 Dynamic quenching includes Förster transfer energy transfer 
(FRET) and Dexter transfer (collisional quenching or electron-transfer quenching). For 
dynamic quenching, the distance between donor and the acceptor needs to be within 20-
100 Å, as the two moieties move closer, reduced fluorescence intensity will result. The 
spectral overlap should be between the donor’s emission and the acceptor’s absorption 
spectra. The relative orientation of the donor and acceptor needs to be approximately 
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parallel. Static quenching requires formation of an intramolecular dimer with unique 
properties, such as unique absorption spectrum or being nonfluorescent.2–5 Therefore, 
appropriate contact between the two moieties is necessary for both mechanisms. It is 
known that planar aromatic dyes such as phenanthrene and pyrene6 may participate in π-π 
stacking, thus prefering a static quenching.  
To improve signal-to-background ratio, the choice of fluorophore and quencher pair is 
critical. A systematic study of quenching efficiencies for different fluorophore and 
quencher pairs has been reported.5 Matching the fluorophore with an effective quencher 
can lead to improvements in detection by reducing the background from the MB in the 
absence of targets.  
DNA-based MBs have become well-known in gene detection, biosensing, bioimaging and 
therapy. However, they are very susceptible to nucleolytic degradation during in vitro and 
in vivo studies. Thus artificial nucleic acids analogues, such as locked nucleic acid (LNA) 
and unlocked nucleic acid (UNA), have been introduced and employed in the applications 
of MBs and light-up probes in recent years.7–9 PNA beacons have also been investigated 
due to their superior hybridization features, resistance to nucleases and proteases, chemical 
robustness, and sequence discrimination.10–12 
To date, various PNA MBs have been developed. A summary of conventional PNA 
beacons will be presented in chapter III. In the development of MBs, background signal 
has always been a critical aspect to consider. On one hand, it could come from the probe 
itself, for example, it is very difficult to achieve complete quenching in a conventional MB 
and this may result in a significant background signal. On the other hand, it also occurs 
from the native fluorescence of many molecular species in the biological environment. 
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These issues deteriorate assay sensitivity and compromise probe selectivity, thus 
complicating the analysis of small molecules, nucleic acids, and proteins in a complex 
sample. Therefore, the challenge to minimize background signal and to tolerate complex 
biological sample interference becomes critical. Researchers around the world have 
successfully modified and synthesized various MBs to suit their needs. Recently, variation 
on the MB theme has been made to improve their function by eliminating false signals, 
increasing specificity, and providing enhanced detection limits. Quencher-free molecular 
beacons (QF-MBs) are one of the significant modifications of the conventional MB, in 
which the quencher moiety has been eliminated. Based on the design, the reported QF-
MBs can be broadly classified into two different types: mono-labelled QF-MBs and dual-
labelled QF-MBs. Mono-labelled QF-MBs contain a fluorophore at the middle or end of 
the oligonucleotide while dual-labelled MBs contain two fluorophores at the stem or at the 
ends. Singly-labeled PNA probes carrying one environmentally sensitive dye, such as 
fluorene,13 pyrene14–17 or thiazole orange have been reported.18–20 MBs containing two 
pyrene fluorophores are archetype of dual-labelled QF-MBs. (Figure 2.1)21 Compared to 
conventional MBs with on/off output patterns, pyrene-based QF-MBs are attractive due to 
unambiguous detection of the target by changes in excimer/monomer ratios.21–23 The 
excimer complex also results in a long fluorescence lifetime (30-60 ns) of the excited state 
of pyrene compared to the auto fluorescence of cellular extracts (~7 ns). In spite of this, 
pyrene has been reported to have low quantum yields when attached to biomolecules and 
relatively short absorption and emission wavelengths which can suffer from interference 
from cellular auto fluorescence.7,24 However, pyrene-modified quencher-free PNA-based 
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QF-MBs are not widely described, with only one based on the modified acpcPNA scaffold 
reported recently.25 
 
Figure 2.1 Schematic representation of pyrene-based QF-MB, which was dually labeled 
with pyrene at the 3’-and 5’-end of single-stranded oligonucleotides with a stem-loop 
structure. In the absence of target DNAs, the “closed” stem-loop conformation 
predominantly emits excimer fluorescence (green) whereas the MB undergoes a dynamic 
conformational change to emit monomer fluorescence (blue) upon hybridization with 
target DNAs21 (copyright 2004 American Chemical Society). 
2.2 Synthesis of QF-PNA beacons 
PNA beacons are usually synthesized by SPPS using standard and modified monomers that 
contain a fluorophore or quencher. However, the synthesis of modified monomers is rather 
laborious and time-consuming. Often, luminophore-functionalized monomers cannot be 
directly introduced into PNA oligomers efficiently due to incompatibility with the chemical 
conditions (acidic or basic) of SPPS. Hence, post-synthetic functionalization of the PNA 
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oligomer represents a viable alternative to potentially reduce the overall synthetic effort, 
as well as introducing a step that is amenable to structural diversification.  
Some post-synthetic methodologies for the preparation of modified PNAs have been 
reported. For example, in 2001, Ikeda and co-workers synthesized an amino-containing 
PNA monomer and successfully functionalized a PNA oligomer through a post-synthetic 
amide bond formation.26 Nevertheless, more convenient and selective methods are needed, 
because some luminophores are unstable under the coupling conditions, or the conditions 
to reveal the amino group concomitantly remove other protecting groups on the oligomer. 
In the same year, click chemistry was described by Sharpless and co-workers,27 after which 
a tremendous number of applications of click reactions appeared. These reactions are 
touted to proceed under mild, simple conditions, being fast, chemoselective, and high 
yielding; thus, these are attractive candidates for the post-synthetic functionalization step. 
The archetypal click reaction, copper(I)-catalyzed Huisgen azide-alkyne cycloaddition 
(CuAAC) yielding the chemically robust 1,4-disubstituted 1,2,3-triazole derivatives,28 was 
an obvious starting point for post-synthetic functionalization of PNA. 
A number of groups have reported modifications of PNA monomers and/or bioconjugation 
of oligomers by using CuAAC.29–31 However, most of those PNA-CuAAC approaches 
were performed in solution. Our attention turned to on-resin CuAAC, because it combines 
advantages of click chemistry and SPPS in which an excess of reactants can be used and 
are easily washed away from the solid support without tedious work up; it is operationally 
easy to perform, and often gives quantitative yields. 
Herein, a post-synthetic method based on on-resin CuAAC was developed and utilized in 
simultaneous functionalization of PNA, which allows the preparation of pyrene-based 
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PNA beacons more efficient. Two pyrene-based PNA beacons, MB1 and MB2, were 
successfully synthesized and evaluated. 
2.3 Results and discussion 
To apply post-synthetic click chemistry to developing PNA MBs, we designed and 
synthesized an azide PNA monomer in which a nucleobase was replaced with an azide 
group31 (Scheme 2.1). One or more azide monomers can be inserted into a PNA sequence 
by automated SPPS in any position without concern for incompatibility.  
 
Scheme 2.1 Synthesis of azide PNA monomer (1). 
In the work of this chapter, two azide-containing PNA sequences (PNA1-Az and PNA2-
Az) have been synthesized via Fmoc SPPS protocol targeting cystic fibrosis (CF), is 
agenetic disease caused by loss or mutation of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (Table 2.1). Then the simultaneous modification of 
PNA1-Az for preparation of pyrene-based QF-MBs by post-synthetic on-resin click 
chemistry was performed (Scheme 2.2). Directly after oligomer synthesis, the resin-bound 
PNA was subjected to CuAAC in the presence of excess 1-ethynylpyrene. The excess 
reagents, solvents, and catalyst were easily washed from the resin, whereas the workup to 
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remove these materials can be laborious in solution-based methods. After cleavage of the 
oligomer from the resin, only the usual HPLC purification was required. By using this 
method, a stemless PNA beacon, MB1, was successfully prepared and characterized. Seitz 
and co-workers first demonstrated that PNA molecular beacon constructs do not require 
the stem-loop structure that is obligate for DNA MBs.13 However, it is conceivable that the 
sequence and identity of the fluorophores might impact the degree of interaction, especially 
in this example, where both proximity and orientation are important in order for the pyrene 
units to effectively π-π stack (excimer formation). Therefore, stem-loop MB2 was 
designed and synthesized by using the same method.  
Shown in Scheme 2.2, azide-containing PNA oligomers (PNA1-Az, PNA2-Az) were 
synthesized by using an azide monomer with automated Fmoc SPPS protocols. Two 
conditions for solid-phase CuAAC have been developed. For condition a, CuI was used as 
the catalyst, and DIPEA was employed to help dissolve copper in the solvent. The resin 
was shaken in the mixture at room temperature under N2. Reaction progress was monitored 
by ESI-MS. The click reaction was observed to be complete after two days. As CuI is not 
stable in the presence of air or moisture, the more robust catalyst system of CuSO4·5H2O, 
along with a reducing agent, sodium ascorbate, was employed for condition b and 
stabilized by N,N’-dimethylethylenediamine (DMEDA). A mixture of 
isopropanol/DMSO/H2O (1:1:2, v/v/v) was used as the solvent. The resin was shaken in the 
aqueous solution at room temperature under N2, and the reaction was deemed complete via 
mass spectrometry after 16 h. The excess reactants and copper complexes were then 
removed by sequentially washing the resin with DMF, CH2Cl2, H2O, MeOH, and DCM. 
After Fmoc deprotection and resin cleavage, the pyrene-based PNA beacons were purified 
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by standard HPLC methods. Characterization of the oligomers was carried out by ESI-MS, 
which showed that two units of pyrene were simultaneously clicked to the PNA oligomer 
quantitatively on the solid support. The resulting oligomers, MB1 and MB2, have been 
characterized by ESI-MS. The peaks corresponding to full-length, fully modified 
oligomers were observed while the mass of “unclicked” sequences were not detected. 
Table 2.1 Oligomers investigated in this study. 
Name   Sequence (5'-3' or N-C)* 
PNA1-Az   K-Az-CTTTCCT T CACTGT-Az-K 
MB1   K-Py-CTTTCCT T CACTGT-Py-K 
PNA2-Az   K-CAT-Az-CTTTCCT C CACTG-Az-ATG-K 
MB2   K-CAT-Py-CTTTCCT C CACTG-Py-ATG-K 
PNA-Ir   K-Ir-CTTTCCT T CACTGT-Ir-K 
CF-A   ACAGTG A AGGAAAG 
CF-T   ACAGTG T AGGAAAG 
CF-G   ACAGTG G AGGAAAG 
CF-C   ACAGTG C AGGAAAG 
*The complementary of mismatched are underlined. 
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Scheme 2.2 General synthesis of PNA MBs by on-resin CuAAC. a) 1-ethynylpyrene (20 
equiv.), CuI (200 equiv.), DIPEA (300 equiv.), THF/pyridine (5:3, v/v); b) 1-ethynypyrene 
(15 equiv.), CuSO4⋅5H2O (30 equiv.), sodium ascorbate (120 equiv.), DMEDA (60 equiv.), 
isopropanol/DMSO/H2O (1:1:2, v/v/v); c) 20% piperidine/DMF followed by TFA/TES 
(95:5, v/v). 
The easily accessible azide PNA monomer has the potential to facilitate screening of 
various PNA constructs. For example, in this work, the resin-bound azide containing PNA 
oligomers (5 µmol synthesis scale) was split into several portions used for various click 
reactions. Thus, without the need to repeat PNA synthesis, different conditions to optimize 
the chemistry for the click reaction were tested. Moreover, different fluorophore alkynes 
could be employed to produce varied PNA probes with similar ease while the traditional 
method requires onerous labour and a relatively large amount of each fluorophore-
containing PNA monomer.  
The stability of the PNA:DNA duplexes was determined by thermal denaturation studies 
after annealing of PNA beacons MB1 and MB2 to the perfectly matched or one-base 
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mismatched (MM) DNA target strands. The Tm values (Table 2.2) show that the matched 
duplex of MB1 demonstrated somewhat typical discrimination over single-MM targets 
(∆Tm=6-9 ºC), whereas the single-stranded MB1 did not display a melt transition. On the 
other hand, MB2, designed with a stem-loop structure of four PNA base pairs and two 
intercalated pyrene units showed an intramolecular Tm that was comparable to its fully 
matched duplex with DNA. This demonstrates that PNA:PNA hybridization is extremely 
stable, and an even shorter stem for PNA MBs should be considered to ensure that the 
stem-loop structure would be disrupted upon hybridization with complementary DNA. 
Interestingly, thermal denaturation studies of MB2 and MM-DNAs showed biphasic 
melting profiles. This might be due to a mixture of single-stranded (SS) PNA and 
PNA:MM-DNA duplex existing together under the experimental conditions. 
Thermal denaturation studies were also carried out to determine the stability of PNA 
MB2:CF RNA duplexes (Table 2.2). The PNA:RNA duplexes showed greater thermal 
stability than the same DNA sequences, yet the discrimination for mismatches remained 
the same (∆Tm=8-10 ºC). Interestingly, the UV melt curves with RNA were monophasic. 
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Table 2.2 Thermal stabilities and switching ratios of duplexes. 
Oligomers[a] Φ[b] B[c] SR[d] Tm (ºC) 
MB1 0.05 2750 -- n.d. 
MB1+ matched DNA 0.06 4540 1.3 59 
MB1 + MM-T DNA 0.09 5090 2.2 51 
MB1 + MM-G DNA 0.1 5690 1.6 53 
MB1 + MM-C DNA 0.1 5110 1.7 50 
MB2 0.12 5630 -- 60 
MB2 + matched DNA 0.07 3030 4.5 59 
MB2 + MM-A DNA 0.04 2240 3.2 46 & 63[e] 
MB2 + MM-T DNA 0.04 2600 3.6 48 & 61[e] 
MB2 + MM-C DNA 0.04 2640 3.5 48 & 64[e] 
MB2 + matched RNA 0.1 2930 6.4 71 
MB2 + MM-A RNA 0.09 2970 5.7 63 
MB2 + MM-T RNA 0.1 3000 5.6 61 
MB2 + MM-C RNA 0.09 4400 5.4 62 
[a] Annealed samples; [b] Quantum yield (0.546 for quinine sulphate in 0.5 M 
H2SO4 as standard [c] Brightness (QY×ε356). [d] Switching ratio 
(F397/F475)ds/(F397/F475)ss; [e] Biphasic melting curves. 
 
It is noteworthy that all mismatched duplexes were stable at room temperature (Tm 
values >25 ºC), indicating that optimum discrimination of mismatched targets could only 
be achieved at a higher temperature. For DNA-based systems, the melting temperatures 
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were much more sensitive to ionic conditions, which can be manipulated to provide assay 
stringency, whereas PNA hybridization is much less affected by ionic conditions.  
To evaluate the ability of pyrene-labeled PNAs to act as molecular beacons, their 
fluorescence emission spectra were recorded in the absence or presence of DNA target 
strands. As shown in Figure 2.2a, broad emission centred at about 475 nm (black squares) 
indicated excimer emission from SS-MB1.The two shorter wavelength emission bands at 
385 and 401 nm represent monomer fluorescence. As expected, only monomer emission 
was observed when MB1 was hybridized to a DNA target. The colour change could be 
readily detected (Figure 2.3). However, the change in excimer/monomer ratios was modest. 
The fluorescence spectra of one-base mismatched duplexes with MB1 were also recorded, 
and the switching ratio (SR), a parameter for judging discrimination, was calculated for all 
duplexes (Table 2.2). The perfectly matched duplex (Table 2.2) had an SR of only 1.3; the 
SRs of MM duplexes are higher, thus indicating that MB1 cannot satisfactorily 
discriminate fully matched targets from mismatched targets at room temperature. We 
hypothesized that the stemless MB1 conformation does not sufficiently favour excimer 
formation; thus, in this construct, a stem-loop structure might be necessary to bias pyrene 
excimer formation. 
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Figure 2.2 Fluorescence spectra of a) MB1 and b) MB2 in the presence of matched DNA. 
Conditions: 2 µM PNA and target in 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 
7, 25 ºC. Excitation:  λex = 345 nm.   
 
Figure 2.3 Fluorescence images at individual strand concentration of 2 µM under 
illumination at λ=365 nm. a) Left, MB1; right, MB1 + matched DNA; b) Left, MB2; right, 
MB2 + matched DNA. 
MB2 exhibited higher fluorescence efficiency than MB1 in terms of its better quantum 
yield (0.12 vs. 0.05) and brightness (5630 vs. 2750). More importantly, the fluorescence 
emission of stem-loop MB2 is shown in Figure 2.2b. Prominent emission at 475 nm 
indicated excimer emission, along with the shorter wavelength emission peaks due to the 
fraction of the population of molecular beacons that possess pyrenes as discrete monomers. 
Likely, the stacking of pyrene chromophores in the stem region of MB2 is partly 
49 
 
responsible for the excimer emission of MB2 being recorded as a shoulder instead of as a 
discrete band. The addition of target DNA caused a significant decrease in the fluorescence 
intensity at 475 nm, indicating the disappearance of excimer. It was observed that the 
monomer emission of the duplex decreased as well in terms of lower quantum yields and 
brightness, implying a quenching phenomenon.32 The origin of the quenching is likely due 
to the adjacent GC base pairs in the sequence of the MB2:DNA duplex. Nevertheless, the 
change in fluorescence of MB2 before and after hybridization with target DNA is obvious 
at room temperature (Figure 2.3b). In contrast to the stemless MB construct, when MB2 
was challenged with the perfectly matched complement, an SR of 4.5 was observed (Table 
2.2), as well as better fluorimetric discrimination of one-base mismatched targets 
(∆SR=0.9-1.3). Moreover, MB2:matched RNA showed the best switch (SR 6.4) and better 
discrimination of mismatched targets (∆SR=0.7-1). However, the change in 
excimer/monomer ratios of MB2 was not as pronounced as that reported for stemless MB 
based on pyrene-modified acpcPNA (SR from 1.1 to 30.8).33 Therefore, 
fluorescence/melting studies were performed to help us understand the relatively poor 
discrimination of PNA:matched duplexes over one-base mismatched duplexes (Figure 2.4). 
It was observed that all matched and one-base mismatched duplexes showed similar 
excimer emission at 25 ºC and ideal differences among SS, matched duplex, and MM 
duplexes at around 50 ºC. This indicates the best discrimination would be achieved when 
fluorescence studies of MB2 are performed at 50 ºC instead of at room temperature. 
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Figure 2.4 Fluorescence-melting spectra of PNA MB2 in the presence of DNA targets 
monitored at 475 nm. λex = 345 nm. 
The formation of PNA:DNA helical structure was investigated by circular dichroism 
measurements. Without the target, MB2 characteristically showed no CD signal (Figure 
2.5). In the presence of a fully matched DNA target, the duplex of MB2 displayed a positive 
Cotton effect at 264 nm, a shoulder at 275 nm, and a positive peak at 220 nm. Similar 
spectral features of one-base MM duplexes were observed and produced weaker CD 
signals than the fully matched duplex. This confirmed that MB2 could form helical 
structures with complementary DNAs. 
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Figure 2.5 CD spectra of MB2 in the presence of DNA targets. Conditions: 2 µM PNA 
and target strands in 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC. 
To judge the hybridization kinetics of MB2, time-dependent fluorescence studies were 
carried out. As shown in Figure 2.6, the fluorescence intensity that represented the change 
in excimer/monomer ratios reached ~87% of the maximum readout within 1 min after the 
addition of fully matched target DNA. This showed the ability of MB2 to rapidly bind 
DNA without an annealing step. 
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Figure 2.6 Time-dependent fluorescence readout of MB2 with addition of target DNA 
(relative emission intensity = the difference between monomer emission intensity at 397 
nm and excimer emission intensity at 475 nm). Conditions: 2 µM PNA and target in 100 
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC. λex = 345 nm. 
The target-response curve shown in Figure 2.7 was measured by fluorescence titration 
under in vivo-like conditions. With the addition of 0-1.2 equiv. of target into a solution of 
2 µm MB2, the change in excimer/monomer ratios (F397-F475) was increased and reached 
a maximum at around 1 equiv. The excess target led to no further spectral changes. 
Furthermore, target titration studies suggested that the matched CF gene could be detected 
at 320 nM at the maximum change in excimer/monomer ratios when MB2 was used as the 
probe. 
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Figure 2.7 The target-response curve of MB2 with the increase of target concentration 
(relative emission intensity = the difference between monomer emission intensity at 397 
nm and excimer emission intensity at 475 nm). Conditions: 2 µM PNA in 100 mM NaCl, 
10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC. λex = 345 nm. Limit of detection (LOD) 
was calculated as 320 nM. 
To test the versatility of this method, the insertion of two iridium complex moieties into a 
PNA sequence by on-resin CuAAC was demonstrated in this work (Scheme 2.3). 
Characterization of the oligomer PNA-Ir by ESI-MS showed that two units of iridium 
complexes were successfully incorporated into the PNA oligomer quantitatively on the 
solid support (Table 2.3). This is in addition to our demonstration of successful insertion 
of single fluorenyl and pyrenyl moieties, as well as a dual pyridyl-modified PNA.31 
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Scheme 2.3 Synthesis of PNA-Ir via on-resin CuAAC. (i) Iridium complex (20 equiv.), 
CuI (200 equiv.), DIPEA (300 equiv.), THF/pyridine 5:3 (v/v) (ii) 20% piperidine/DMF 
followed by TFA/TES 95:5 (v/v). 
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Table 2.3 ESI-MS data of PNA sequences in this study.[a] 
PNA 
Sequence Found m/z 
[M+H]+ 
Calc. m/z 
[M+H]+ 
1-Az K-Az-CTTTCCTTCACTGT-Az-K 4547.87  4547.89 
 
 
  
MB1 K-Py-CTTTCCTTCACTGT-Py-K 4776.90 4776.97 
 
 
  
2-Az K-CAT-Az-CTTTCCTCCACTG-Az-ATG-K 5891.08 5890.42 
 
 
  
MB2 K-CAT-Py-CTTTCCTCCACTG-Py-ATG-K 6121.45 6120.51 
 
 
  
PNA-
Ir 
K-Ir-CTTTCCTTCACTGT-Ir-K 
5683.79 5683.14 
    
[a] Az = Azide monomer, Py = triazole-linked pyrene monomer. 
2.4 Conclusion 
In summary, we have proposed a versatile and convenient method to develop new PNA 
molecular beacons by using on-resin click chemistry. The modification of more than one 
position of a PNA oligomer could be performed in a single step and lends itself to divergent 
syntheses of modified PNAs. Two quencher-free PNA beacons were designed and 
synthesized by using this method, and their properties were investigated. (Figure 2.8) 
Compared with stemless beacon MB1, stem-loop beacon MB2 showed better 
discrimination upon hybridization with target sequences based on changes in 
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excimer/monomer ratios, indicating that the stem region is necessary in the design of PNA 
MBs due to the variable interactions between pyrene and neighboring base sequences. 
Under in vivo-like conditions, MB2 showed rapid binding and response to target DNA. 
However, to achieve an excimer-monomer switching ratio as high as the previously 
reported pyrene-based MBs, further modification of MB2 is still need. 
 
Figure 2.8 Top:  PNA sequences used for the molecular beacons, MB1 and MB2, 
illustrating the placement of the pyrene monomer (X).  N' = N-terminus, C' = C-terminus, 
K = L-lysine, target sequence underlined.  Bottom:  Conceptual representation of stemless 
and stem-loop PNA beacons and their response. 
2.5 Experimental  
Synthesis of PNA sequences (PNA1-Az, PNA2-Az) 
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide 
synthesizer. TGR Tentagel R-Lys(Boc)-Fmoc resin (loading 0.045 mmol/g) and PEGA-
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Lys(Boc)-Fmoc resin (loading 0.113 mmol/g) were used for condition a and condition b, 
respectively. The synthesis was terminated without the final Fmoc deprotection. A small 
portion of the resin was taken for characterization and the oligomer was 
cleaved/deprotected under standard conditions for the characterization of PNA1-Az and 
PNA2-Az by ESI-MS. Other portions of the resin were taken and manipulated in manual 
peptide synthesis vessels. 
 
General procedure for on-resin click chemistry 
Condition a: The resin with PNA-Az was placed in THF:pyridine (5:3) (0.8 mL) in a 
peptide synthesis vessel. 1-Ethynyl pyrene (20 equiv.), CuI (200 equiv.), DIPEA (300 
equiv.) were added to the resin successively. The resin was shaken in the mixture at room 
temperature under N2 for 2 days. After the reaction was deemed complete by Waters LCT 
Premier ESI-MS, the solvent was drained and the resin was washed sequentially with DMF, 
DCM, H2O, MeOH and finally DCM.  
 
Condition b: 1-Ethynylpyrene (15 equiv.) in isopropanol: DMSO (1:1) (0.5 mL), 
CuSO4·5H2O (30 equiv.) in H2O (0.5 mL), NaAscorbate (120 equiv.) in H2O (0.5 mL) and 
DMEDA (60 equiv.) were added to the resin in a peptide vessel. The resin was shaken at 
room temperature under N2 overnight. After the reaction was deemed completed by ESI-
MS, the solvent was drained and the resin was washed sequentially with DMF, DCM, H2O, 
MeOH and finally DCM. 
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After condition a or b, the resin was shaken in 2 mL 20% piperidine/DMF for 15 min to 
remove the fmoc protecting group. Then PNA was cleaved, purified and characterized 
following by our previously reported procedure.34 
 
Quantification of PNA oligomers 
UV-visible spectrophotometer was used to determine the concentrations of PNA solutions. 
10 µL of stock PNA sample was diluted to 1 mL for quantification and the absorbance at 
260 nm of the sample was measured. 13700, 8800, 6600, 11700 and 2840016 M-1cm-1 were 
used as ε260 values of A, T, G, C and the pyrene-modified monomer, respectively. The 
equation below was used for calculation.  
c	(µM)=
1000×A260
13.7NA		8.8NT		11.7NG		6.6NC		28.4Npy
 
 
Thermal denaturation experiments of oligomers 
UV melting experiments were carried out to measure the Tm values of oligomers in this 
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM 
EDTA, pH 7.0. Samples at 2 µM concentration were heated to 95 ºC, cooled to room 
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed 
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average 
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ± 
0.9 ºC. Tm values were estimated for cooperative transitions by the first derivative method. 
Temperature dependent UV spectra that lacked upper and lower baselines, lacked 
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were 
deemed not be to cooperative transitions. 
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Fluorescence studies of oligomers 
Samples for all fluorescence studies were prepared in a quartz cell (path length: 1 cm) in 
the same ionic conditions as for the denaturation experiments. Parameters for fluorescence 
spectra are: excitation wavelength, 345 nm; scanning range, 350-600 nm; data interval, 0.1 
nm; scan rate: 1 nm/s; temperature, 25 ºC. Fluorescence denaturation was performed from 
20 to 80 ºC at a temperature ramp rate of 0.5 ºC/min.  
 
In the target titration fluorescence studies, a series of solutions containing the 
corresponding DNA target (0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4 µM) were 
mixed with MB2 (2 µM). The LOD value was defined as the lowest concentration of the 
target in a series detected at the corresponding maximum change in excimer-monomer 
ratios such that the fluorescence signal to noise ratio (S/N) relative to the blank solution of 
a medium salt buffer was ≥3. 8,32 
 
Calculation of photophysical properties 
For calculation of quantum yield (QY), quinine sulfate in 0.5 M H2SO4 (Φ = 0.546, 
excitation at 355 nm) was used as standard material.7 The QYs of MB1, MB2 and their 
duplexes were calculated according to a previous report.8 Absorbance at 356 nm was 
measured and used for excitation of the oligomers. Refractive indices were 1.333. For 
calculation of extinction coefficients of oligonucleotides, Beer–Lambert law (A = ε l c, l: 
1 cm, c: 2 µM) was used. The brightness was expressed by QY × ε356. 
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CD studies of oligomers 
CD spectra where measured under the same conditions of concentration and ionic strength 
as for denaturation experiments. Cuvette path length was 1 mm and scans were made from 
400-200 nm at a rate of 100 nm/min with a data pitch of 0.5 nm and response time of 0.5 
sec. Scans were averaged over 10 accumulations and are presented molar ellipticity 
(deg·cm2·dmol-1). Savitzky-Golay smoothing method was used.  
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2.6 Supplementary Information 
 
 
Figure 2.9 ESI-MS spectra of 1-Az; calculated mass for C188H245N82O56: 1137.7289 
[M+4H] 4+ (top), 910.3847 [M+5H] 5+ (bottom). 
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Figure 2.10 ESI-MS spectra of MB1 calculated mass for C209H254N82O54: 1194.9991 
[M+4H] 4+ (top), 956.2008 [M+5H] 5+ (bottom). 
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Figure 2.11 ESI-MS spectra of PNA 2-Az; calculated mass for C241H309N113O69: 
1179.5729 [M+5H] 5+ (top), 983.1454 [M+6H] 6+ (bottom).  
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Figure 2.12 ESI-MS spectra of MB2; calculated mass for C262H319N113O67: 1225.6352 
[M+5H]5+ (top), 1021.5307 [M+6H]6+ (bottom). 
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Figure 2.13 ESI-MS spectra of PNA-Ir; calculated mass for C241H282Ir2N90O54: 1137.4338 
[M+5H]5+ (top), 948.0295 [M+6H]6+ (bottom); 
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Figure 2.14 HPLC-UV absorption spectra of PNA at 265 nm. (a) MB1; (b) MB2. 
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12. CHAPTER III: SYNTHESIS OF CONVENTIONAL PNA 
MOLECULAR BEACONS VIA A CONVENIENT “CLICK-
COUPLE-CLICK” APPROACH 
3.1 Introduction to conventional PNA beacons 
The significance of molecular beacon (MB) technology was discussed in Chapter II. The 
focus of this chapter is on the development of synthetic strategies for conventional PNA 
beacons. The first PNA-based MB that contained a PNA probe domain and a hybrid PNA-
DNA stem was developed by Lizardi and co-workers in 1998 (Figure 3.1).1 The reporter 
groups used in this study were 7-amino-4-methylcoumarin-3-acetic acid (AMCA) as the 
fluorophore and p-(dimethylaminophenylazo)benzoic acid (DABCYL) as the quencher. 
The synthetic scheme shows that DABCYL-succinimidyl ester was coupled to the DNA 
sequence which possessed an aminated thymidine by formation of a stable carboxamide. 
The AMCA was coupled to the amino group of glycine on PNA strand via the same 
reaction (Scheme 3.1). Then the modified DNA and PNA were conjugated by formation 
of disulfide. It has been found that this probe undergoes a fluorescent change in the 
presence of a complementary DNA target.  
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Figure 3.1 Structure and sequence of the first PNA-DNA molecular beacon1 (copyright 
1998 Elsevier). 
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Scheme 3.1 Synthetic scheme of first PNA-based MB1 (copyright 1998 Elsevier). 
Before long the synthesis of PNA MBs based on solid-phase peptide synthesis was 
investigated and disclosed. Different from conventional DNA MB constructs which 
contain a stem-loop structure, PNA MBs are usually stemless, due to the tendency of PNA 
to form secondary structures that results in the appended FRET pair (usually at opposite 
termini) being in close proximity. For example, Seitz reported a stemless PNA molecular 
beacon in 2000.2 SPPS of PNA was performed by using a hydroxycrotyl-oligoethylene 
glycol-n-alkanoyl (HYCRON) anchor on the solid support,3 which is stable under acid- or 
base-deprotection protocols (Scheme 3.2). The protection groups of the nucleobases on the 
resin-bound PNA were then removed, followed by treatment with DABCYL-
hydroxysuccinimide ester (SE) in order to attach the quencher to PNA via amide formation. 
However, the unprotected thiol groups were found to readily form disulfide. Thus, a 
dithiothreitol reduction was used in order to liberate the thiol groups, to which the 5-(2-
aminoethylamino)1-naphthalene sulfonic acid (EDANS) group was attached by a selective 
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alkylation with 5-(2’-iodoacetamidoethyl)aminonaphthalene sulfonic acid (IAEDANS). 
Finally, the resin was cleaved by using a Pd0-catalyzing allyl transfer with morpholine 
scavenger. The resulting PNA beacon was demonstrated to fluoresce weakly in the single-
strand state, but showed a vivid fluorescence enhancement after hybridization with a 
complementary oligonucleotide. 
 
Scheme 3.2 Solid-phase synthesis of doubly labeled PNA as probes2 (copyright 2000 John 
Wiley and Sons). 
Kitagawa et al. also described the synthesis of a PNA MB in 2002.4 They first prepared a 
DABCYL-containing PNA monomer and incorporate it into PNA oligomers via Boc-based 
SPPS. However, the DABCYL moiety decomposed during the step of cleaving MBHA 
resin using a TFMSA/TFA solvent system. Therefore, they started to consider a post-
synthetic method to introduce DABCYL into the PNA oligomer. Fmoc/Cbz-protected 
resin-bound PNA was prepared and treated with piperidine to remove Fmoc group but 
retain Cbz groups on all nucleotides as well as the C-lysine. The fluorescein moiety could 
then be coupled to PNA. Subsequently, the removal of Cbz group was accomplished 
followed by attachment of DABCYL to PNA. The conjugation of both fluorescein and 
DABCYL is achieved via amide formation.  
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Due to the desirable and useful properties of PNA, PNA MBs have become commercially 
available and the applications of PNA MBs have been extensively investigated.5–12 In some 
studies, the fluorophore and quencher were conjugated to PNA oligomers either via the ε-
amino group of Lys or the N’-amino group of Glu (e.g., fluorescein-E-
GCTGCCTCCCGTAGGA-K-K-DABCYL). Success was achieved by using PNA to 
detect and quantify rRNA in solution.8 Additionally, PNA MB was able to quantify 16S 
rRNA of specific populations in RNA extracts of environmental samples for the genera 
Dechloromonas and Dechlorosoma.9 Petersen et al. reported that short PNA beacons are 
effective for real-time PCR allelic discrimination of SNP.10 PNA MB was also 
demonstrated useful for the detection of PCR amplicons in droplet-based microfluidic 
devices.11 Two stemless PNA beacons were synthesized later by Totsingan et al. for the 
detection of full-matched or single mismatched DNA and showed high mismatch 
recognition via ion exchange HPLC.12 
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Scheme 3.3 Synthesis of FIT probes using Thiazole Orange (TO) as a Fluorescent Base in 
PNAs13 (copyright 2005 John Wiley and Sons). 
In 2005, Seitz et al. developed FIT (forced intercalation) PNA fluorescent probes to 
distinguish single-base mutation under non-stringent hybridization condition.5,13–15 These 
PNA probes were demonstrated sensitive hybridization probes with outstanding 
fluorescence enhancements upon hybridization. In the original FIT probes, the intercalator 
dye thiazole orange (TO) serves as a base surrogate. The TO fluorophore was first equipped 
with carboxyalkyl spacers of varying length in order to enable coupling with the PNA 
backbone (Scheme 3.3). As the central building block, an orthogonally protected backbone, 
Fmoc/Aloc-protected aminoethylglycine was incorporated during the Fmoc-based PNA 
SPPS. However, the coupling of TO moiety with the backbone that contains one free amino 
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group was unsuccessful due to the poor solubility of TO derivatives and low reactivity of 
the N-alkyl amino acid structure in oligomer 4. Ultimately, pyridinium p-toluenesulfonate 
was found to help increase the solubility of TO and enable the coupling with resin-bound 
PNA oligomer 4. FIT probes were further modified by adding an additional Lys conjugated 
with a fluorophore on the N-terminus as stemless PNA beacons (Figure 3.2).14,16 The shift 
of the emission wavelength from the intercalator dye to the near infrared dye with high 
sensitivity and specificity at nonstringent conditions has been observed, which may be 
useful for reducing background 
 
Figure 3.2 Comparison of A) DNA molecular beacons with B) stemless FIT- PNA beacons 
in the detection of complementary nucleic acids. In stemless FIT-PNA beacons, an 
intercalator dye such as thiazole orange (TO) serves as a base surrogate that signals 
stacking against matched base pairs by FRET to a near infrared dye such as NIR667. 
PNAs.14 (copyright 2008 John Wiley and Sons) 
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in single-base-mutation analyses and in live-cell RNA imaging. Similarly, a thiazole 
orange modified PNA MB (TO-PNA-MB) was reported by Yavin et al. and demonstrated 
effective to detect endogenous K-ras mRNA in living cells at a single base resolution.17 
Although useful PNA MBs have been synthesized and have shown promise in various 
applications, the limitations of the conventional methods for functionalization of PNA 
cannot be neglected. Synthesis of a luminophore-containing PNA monomer is always 
tedious and labour-intensive. Insertion into a PNA sequence requires a large amount of 
precious modified monomer. Moreover, some modified PNA monomers are not 
compatible with SPPS or coupling yield is poor. Thus post-synthetic functionalization has 
been attempted. However, the current approach is still based on the “deprotection-
coupling-deprotection-coupling” scheme, which is obviously not optimum. In order to 
achieve orthogonal functionalization, different protecting strategies are necessary, in which 
the conditions to remove the various protecting groups and the conditions to cleave the 
resin are usually complicated or harsh, making the procedure difficult to operate. Moreover, 
some fluorophores or quenchers are insoluble or unstable under coupling conditions. 
Additionally, it is still tedious and not very chemo-selective. Minor change of the substrates, 
solvents or reaction conditions would lead to failure of the whole process or low yields. 
Therefore, more robust and higher chemically selective post-synthetic methods are needed 
for developing PNA MBs. Copper-catalyzed click chemistry is obviously one of the most 
promising choices. My attention turned to on-resin CuAAC resulting in successful results 
of preparation of pyrene-based quencher-free PNA MBs (Chapter 2). However, to the best 
of our knowledge, click chemistry has not been applied in the development of conventional 
PNA beacons which contain different reporters. Hence, in this chapter a “click-couple-
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click” post-synthetic approach, which is based on microwave-assisted on-resin CuAAC for 
divergent synthesis of conventional PNA beacons is described. This approach has the 
potential to significantly simplify the procedure of sequentially attaching fluorophore and 
quencher to PNA oligomers. It may also facilitate the screening of fluorophores or 
quenchers in the development of most effective PNA MBs. 
3.2 Results and discussion 
An azide monomer has been designed and synthesized in which a nucleobase was replaced 
with an azide group.18 It was incorporated into a PNA sequence by automated SPPS in the 
position close to C-terminus. DABCYL, the quencher used in this study, could be attached 
to PNA oligomer via microwave-assisted on-resin CuAAC followed by coupling reaction 
of an additional azide monomer to PNA. To improve the efficiency of on-resin CuAAC, 
another chelator ligand, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), was used in 
this study.19,20 The use of THPTA reduces the tendency for copper(I) species to aggregate, 
while the kinetically labile triazolyl-copper binding allows rapid ligand exchange 
providing the alkyne and azide substrates with access to the copper center. In addition, the 
3-hydroxypropyl group of THPTA enhances the aqueous solubility of the ligand which is 
desired in our click conditions. Moreover, the use of THPTA facilitate the removal of 
copper from the resin, which is crucial for the next step of coupling reaction. The 
functionalized PNA was subjected to Fmoc deprotection and capping on the N-terminus. 
A fluorophore-containing alkyne would be then clicked to the oligomer via the same click 
reaction. After cleavage of resin, the resulting crude PNA was purified by HPLC and 
characterized by ESI-MS. By using “click-couple-click”, four PNA MBs, Py-1-Q, 
Acridone-1-Q, Acridine-1-Q and Fluorescein-1-Q, were first synthesized (Table 3.1).  
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Scheme 3.4 General synthesis of conventional PNA beacons via “click-couple-click”. a) 
(E)-4-((4-ethynylphenyl)diazenyl)-N,N-dimethylaniline (7.5 equiv.), CuSO4⋅5H2O (15 
equiv.), sodium ascorbate (60 equiv.), THPTA (30 equiv.), isopropanol/DMSO/H2O (1:1:2, 
v/v/v), microwave 80 oC, 5 min; b) i) Fmoc azide monomer (5 equiv.), DIPEA (10 equiv.), 
HBTU (5 equiv.), DMF, room temperature, 1.5 hours; ii) 20% piperidine/DMF; iii) 
Ac2O/pyridine/DMF (1:25:25, v/v/v) c) i) same as a except that fluorophore-containing 
alkynyl molecules were used instead of quencher; ii) TFA/TES (95:5, v/v). 
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Table 3.1 Oligomers investigated in this study. 
Name Sequence (5'-3' or N-C) 
Fmoc-1-Az CTTTCCTTCACTGT-Az-K 
Fmoc-2-Az CATCTTTCCTTCACTGTTG-Az-K 
Fmoc-1-Q CTTTCCTTCACTGT-Q-K 
Fmoc-2-Q CATCTTTCCTTCACTGTTG-Q-K 
pyrene-1-Q pyrene-CTTTCCTTCACTGT-Q-K 
acridone-1-Q acridone-CTTTCCTTCACTGT-Q-K 
acridine-1-Q acridine-CTTTCCTTCACTGT-Q-K 
Fluorescein-1-Q Fluorescein-CTTTCCTTCACTGT-Q-K 
pyrene-2-Q pyrene-CATCTTTCCTTCACTGTTG-Q-K 
Fluorescein-2-Q Fluorescein-CATCTTTCCTTCACTGTTG-Q-K 
CF-A* ACAGTG A AGGAAAG 
CF-MM-T* ACAGTG T AGGAAAG 
CF-MM-G* ACAGTG G AGGAAAG 
CF-MM-C* ACAGTG C AGGAAAG 
* CF = cystic fibrosis gene; CF-A is fully matched; MM-T, MM-G, MM-C are sequences 
with mismatched T, G, C respectively. 
The stability of the PNA:DNA duplexes was determined by thermal denaturation studies 
after annealing of three PNA beacons to the perfectly matched or one-base mismatched 
(MM) DNA target strands. The Tm values (Table 3.2) show that the matched duplex of all 
PNA beacons demonstrated good discrimination over one base-MM targets (∆Tm=10-20 
ºC), whereas the single-stranded PNAs did not display a melt transition. However, one 
81 
 
base-MM duplexes all have melting temperatures above 42 ºC, indicating that no 
discrimination between matched and one-base MM duplexes could be detected at room 
temperature.  
Table 3.2 Thermal stabilities of duplexes. Conditions:1 µM PNA and target in 100 mM 
NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. 
Oligomers[a] Tm (ºC) ∆Tm (ºC)
pyrene-1-Q nd -- 
pyrene-1-Q + matched DNA 60 -- 
pyrene-1-Q + MM-T 49 -11 
pyrene-1-Q + MM-G 50 -10 
pyrene-1-Q + MM-C 44 -16 
acridone-1-Q nd -- 
acridone-1-Q + matched DNA 62 -- 
acridone-1-Q + MM-T 44 -18 
acridone-1-Q + MM-G 50 -12 
acridone-1-Q + MM-C 42 -20 
acridine-1-Q nd -- 
acridine-1-Q + matched DNA 61 -- 
acridine-1-Q + MM-T 46 -15 
acridine-1-Q + MM-G 49 -12 
acridine-1-Q + MM-C 42 -19 
Fluorescein-1-Q -- -- 
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Fluorescein-1-Q + matched DNA 63 -- 
Fluorescein-1-Q + MM-T 46 -17 
Fluorescein-1-Q + MM-G 51 -12 
Fluorescein-1-Q + MM-C 48 -15 
pyrene-2-Q nd -- 
pyrene-2-Q + matched DNA 62 -- 
pyrene-2-Q + MM-T 47 -15 
pyrene-2-Q + MM-G 49 -13 
pyrene-2-Q + MM-C 52 -10 
Fluorescein-2-Q 48 -- 
Fluorescein-2-Q + matched DNA 63 -- 
Fluorescein-2-Q + MM-T 48 -15 
Fluorescein-2-Q + MM-G 49 -14 
Fluorescein-2-Q + MM-C 47 -16 
[a] Annealed samples; 
To evaluate the ability of the PNAs to act as molecular beacons, their fluorescence emission 
spectra were recorded in the absence or presence of DNA target strands at room 
temperature.  As shown in Figure 3.3a, the emission of matched duplex showed slightly 
higher fluorescence intensity than that of single stranded pyrene-1-Q. Expectedly, the 
discrimination of one-base MM duplexes from the matched duplex was not observed, 
although MM-G and MM-C duplexed yielded same fluorescence intensity as that from the 
SS PNA. However, emission of matched acridone-1-Q did not exhibit higher fluorescence 
intensity than SS PNA, indicating no “turn-on” effect of acridone-1-Q as a MB. 
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Interestingly, acridine-1-Q and its duplexes did not show fluorescence whereas high 
fluorescence intensity was found after the samples were heated for hours, suggesting 
decomposition of 9-aminoacridine.21 In the state of single strand, Fluorescein-1-Q still 
showed comparable fluorescence to that from matched duplex, indicating low quenching 
efficiency. 
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Figure 3.3 Fluorescence spectra of pyrene-1-Q. Conditions:1 µM PNA and target in 100 
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (pyrene-1-Q) = 345 nm. 
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Figure 3.4 Fluorescence spectra of acridone-1-Q. Conditions:1 µM PNA and target in 100 
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (acridone-1-Q) = 390 nm. 
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Figure 3.5 Fluorescence spectra of acridine-1-Q. Conditions:1 µM PNA and target in 100 
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (acridine-1-Q) = 395 nm.  
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Figure 3.6 Fluorescence spectra of Fluorescein-1-Q. Conditions:1 µM PNA and target in 
100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (Fluorescein-1-Q) = 
493 nm.  
To circumvent the weak “light-on” effect and poor discrimination of stemless PNA 
beacons, a stem-loop PNA beacon which contains one fluorophore and one quencher was 
designed and prepared. Considering that hairpin structure PNA was too stable to measure 
in water18, a PNA sequence 2 with a one-base mismatched stem was synthesized via Fmoc 
SPPS followed by “click-couple-click” of 2 to yield pyrene-2-Q and Fluorescein-2-Q by 
using pyrene and fluorescein as the fluorophores (Table 3.1).  The successful preparation 
of pyrene-2-Q and Fluorescein-2-Q demonstrated that our “click-couple-click” method is 
not sequence-sensitive, which would be of great benefit in developing various PNA MBs.  
Thermal studies were performed to investigate the stability of these two stem-loop PNA 
MBs. Surprisingly, the melting curves of pyrene-2-Q did not show binding, indicating no 
stem was formed. Matched duplex of pyrene-2-Q has been found to have good 
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discrimination over the one-base mismatched targets (10-15 oC) (Table 3.2). However, the 
melting profiles of Fluorescein-2-Q displayed a Tm value of 48 oC and decent 
discrimination between matched and one-base mismatched duplexes (14-16 oC), 
demonstrating weak binding of the stem region of PNA oligomer 2.  
In order to assess the ability as PNA MBs of Py-2-Q and Fluorescein-2-Q, fluorescence 
studies were carried out. Disappointedly, their SS, matched duplex and MM’s all showed 
similar fluorescence intensity, suggesting ineffective quenching.  
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Figure 3.7 Fluorescence spectra of pyrene-2-Q. Conditions:1 µM PNA and target in 100 
mM NaCl, 10 mM NaH2PO4,0.1 mM EDTA, pH 7, 25oC. λex (pyrene-2-Q) = 345 nm. 
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Figure 3.8 Fluorescence spectra of Fluorescein-2-Q. Conditions:1 µM PNA and target in 
100 mM NaCl, 10 mM NaH2PO4,0.1 mM EDTA, pH 7, 25oC. λex (Fluorescein-2-Q) = 
493 nm.  
3.3 Conclusion 
 
Figure 3.9 Synthesis of conventional PNA beacons via “click-couple-click”. 
In this chapter, an approach based on on-resin “click-couple-click” method has been 
developed (Figure 3.9). It has several advantages: 1) fast; the microwave-assisted CuAAC 
only takes 5 minutes and the coupling of second azide monomer 1.5 hours. the whole 
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synthetic procedure of “click-couple-click” could be completed within 3 hours giving 
quantitative yields without the need of preparing modified PNA monomers or extremely 
different reaction conditions; 2) robust; the click reaction is mild and highly chemically 
selective without any incompatibility issue with other functional moieties on reactants; the 
reaction condition is operated easily because it is not sensitive to water, oxygen or light; 3) 
facile; like other post-synthetic methodologies, multi-functionalization of PNA oligomers 
could be achieved in one step; the resin-bound PNA-Q may be split into portions and each 
portion would be used for the click of various fluorophores; in this way, a series of PNA 
beacons could be synthesized and evaluated; this is also helpful in screening useful 
fluorophores for the application of PNA MBs; 4) convenient; only washing the resin with 
solvents is required for the work up that is operationally simple and fast; only final HPLC 
purification after resin cleavage is needed.  
In spite of convenience and versatility of “click-couple-click” method for the development 
of PNA MBs have been demonstrated, the PNA MBs did not yield “turn-on” results or 
discrimination of single-base mismatch at room temperature. The observed poor quenching 
effect could be influenced by the sequence, as other studies have shown promising results 
by using Fluorescein and DABCYL in stemless PNA MBs.4,5,8,18 Further studies are aimed 
to improve the ability of PNA MBs such as attachment of two or more DABCYL molecules 
on one end of the sequence or use of a different type of quencher to improve the quenching 
effects. 
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3.4 Experimental  
 
Synthesis of Fmoc-1-Az and Fmoc-2-Az 
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide 
synthesizer. SpheriTide-Lys(Boc)-Fmoc resin (loading 0.057 mmol/g) was used. The 
synthesis was terminated without the final Fmoc deprotection. A small portion of the resin 
was taken for characterization and the oligomer was cleaved/deprotected under standard 
conditions for the characterization of Fmoc-1-Az and Fmoc-2-Az by Waters LCT Premier 
ESI-MS. Other portions of the resin were taken and manipulated in manual peptide vessels. 
 
General procedure for microwave on-resin click chemistry 
The resin with PNA-Az was placed in isopropanol (0.25 mL) in a peptide vessel. Alkyne 
(7.5 equiv.) in DMSO (0.25 mL), sodium ascorbate (60 equiv.) in water (0.2 mL), THPTA 
(30 equiv.) in water (0.2 mL) and CuSO4·5H2O (15 equiv.) in water (0.1 mL) were added 
to the resin successively. The resin was heated to 80 oC for 5 min by using CEM Discover 
microwave reactor. After this, the solvent was drained and the resin was washed 
sequentially with DMF, DCM, H2O, DMF and finally DCM. 
 
General procedure for on-resin coupling reaction 
The resin with PNA-Q was shaken in 2 mL 20% piperidine/DMF for 15 min to remove the 
Fmoc protecting group and washed with DMF as well as DCM. Fmoc azide monomer (5 
equiv.) was stirred in DMF (3 mL) in a round bottom flask on ice. HBTU (5 equiv.) and 
DIPEA (10 equiv.) were added into the flask. The mixture was stirred on ice for 15 min 
and added to the resin. The resin was then shaken at room temperature for 1.5 hr. After the 
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reaction, the solvent was drained and the resin was washed with DMF as well as DCM. 
The resin was then shaken in 2 mL 20% piperidine/DMF for 15 min to remove the terminal 
Fmoc group and shaken in 3 mL Ac2O/pyridine/DMF (×2) for 15 min to cap the terminal 
amine group. After “click-couple-click”, PNA was cleaved, purified and characterized 
following by our previously reported procedure.22 
Table 3.3 ESI-MS data of PNA sequences in this study.[a] 
Name Sequence (5'-3' or N-C) 
Found m/z 
[M+H]+ 
Calc.  
m/z 
[M+H]+   
Fmoc-1-Az CTTTCCTTCACTGT-Az-K 4238.3296 4238.1883 
Fmoc-2-Az CATCTTTCCTTCACTGTTG-Az-K 5588.1495 5588.4866 
Fmoc-1-Q CTTTCCTTCACTGT-Q-K 4487.6560 4487.5036 
Fmoc-2-Q CATCTTTCCTTCACTGTTG-Q-K 5837.9668 5837.8019 
Fmoc-Az-1-Q Fmoc-Az-CTTTCCTTCACTGT-Q-K 4670.9842 4670.6735 
Fmoc-Az-2-Q Fmoc-Az-CATCTTTCCTTCACTGTTG-Q-K 6021.0658 6020.9719 
Pyrene-1-Q Pyrene-CTTTCCTTCACTGT-Q-K 4716.31 4716.745 
Acridone-1-Q Acridone-CTTTCCTTCACTGT-Q-K 4725.1156 4725.753 
Acridine-1-Q Acridine-CTTTCCTTCACTGT-Q-K 4722.7174 4722.7524 
Fluorescein-1-Q Fluorescein-CTTTCCTTCACTGT-Q-K 4903.8030 4903.8539 
Pyrene-2-Q Pyrene-CATCTTTCCTTCACTGTTG-Q-K 6067.0258 6067.0434 
Fluorescein-2-Q Fluorescein-CATCTTTCCTTCACTGTTG-Q-K 6253.9048 6254.1522 
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a Az = Azide monomer, Q = triazole linked DABCYL monomer, Pyrene = triazole-linked 
pyrene monomer, Acridone = triazole-linked acridone monomer, Acridine = triazole-
linked acridine monomer, Fluorescein = triazole-linked acridine monomer. 
 
Calculation of the extinction coefficient for triazole linked DABCYL monomer, 
triazole-linked acridone monomer and triazole-linked acridine monomer 
The triazole monomers were prepared by Ms. Christie Ettles. A stock solution of 
luminophore-triazole compounds was prepared in 10% DMSO/H2O (1 mg in 1.0 mL). 
From this solution an intermediate diluted solution was prepared, which was used to 
prepare the final solutions with a 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, amd 70 µL 
of the diluted solution in 1 mL H2O. Each solution was prepared in triplicate and the 
absorbance of the solutions were evaluated within the range of 200-500 nm at a scan speed 
of 600 nm/min. 
 
Figure 3.10 Unpublished structures of triazole linked DABCYL monomer, triazole-linked 
acridone monomer and triazole-linked acridine monomer (from left to right). 
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Quantification of PNA oligomers 
UV-visible spectrophotometer was used to determine the concentrations of PNA solutions. 
10 µL of stock PNA sample was diluted to 1 mL for quantification and the absorbance at 
260 nm of the sample was measured. 13700, 8800, 6600, 11700, 2490, 28400,23 42870, 
43740 and 2100024 M-1cm-1 were used as ε260 values of A, T, G, C, pyrene-modified, 
acridone-modified and acridine-modified monomer, respectively. The equation A=εcl was 
used for calculation. ε260 of each PNA MB was the sum of the extinction coefficients of the 
individual bases that comprises the oligomer. 
 
Thermal denaturation experiments of oligomers 
UV melting experiments were carried out to measure the Tm values of oligomers in this 
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM 
EDTA, pH 7.0. Samples at 1 µM concentration were heated to 95 ºC, cooled to room 
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed 
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average 
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ± 
0.9 ºC. Tm values were estimated for cooperative transitions by the first derivative method. 
Temperature dependent UV spectra that lacked upper and lower baselines, lacked 
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were 
deemed not be to cooperative transitions. 
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Fluorescence studies of oligomers 
Samples for all fluorescence studies were prepared in a quartz cell (path length: 1 cm) in 
the same ionic conditions as for the denaturation experiments. Parameters for fluorescence 
spectra are: excitation wavelength, 345 nm; scanning range, 350-600 nm; data interval, 0.1 
nm; scan rate: 1 nm/s; temperature, 25 ºC.  
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3.5 Supplementary information 
 
 
Figure 3.11 ESI-MS spectra of Fmoc-1-Az calculated mass for C176H223N75O53: 
1413.4014 [M+3H] 3+, 1060.3030 [M+4H] 4+. 
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Figure 3.12 ESI-MS spectra of Fmoc-1-Q calculated mass for C192H238N78O53: 898.3070 
[M+5H] 5+, 748.7572 [M+6H] 6+. 
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Figure 3.13 ESI-MS spectra of Fmoc-Az-1-Q calculated mass for C198H247N83O55: 
1168.4243 [M+4H] 4+, 934.9411 [M+5H] 5+. 
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Figure 3.14 ESI-MS spectra of pyrene-1-Q calculated mass for C203H249N83O54: 944.1554 
[M+5H]5+, 786.9641 [M+6H]6+. 
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Figure 3.15 ESI-MS spectra of acridone-1-Q calculated mass for C201H252N84O55: 
1182.1942 [M+4H] 4+, 945.9569 [M+5H] 5+. 
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Figure 3.16 ESI-MS spectra of acridine-1-Q calculated mass for C201H251N85O54: 
945.3568 [M+5H] 5+, 787.9653 [M+6H]6+. 
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Figure 3.17 ESI-MS spectra of Fluorescein-1-Q calculated mass for C209H254N84O60: 
981.5771 [M+5H] 5+, 818.1489 [M+6H]6+. 
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Figure 3.18 ESI-MS spectra of Fmoc-2-Az calculated mass for C230H290N102O69: 932.2544 
[M+6H] 6+, 799.2192 [M+7H] 7+. 
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Figure 3.19 ESI-MS spectra of Fmoc-2-Q calculated mass for C246H305N105O69: 973.8069 
[M+6H] 6+. 
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Figure 3.20 ESI-MS spectra of Fmoc-Az-2-Q calculated mass for C252H314N110O71: 
1004.3353 [M+6H] 6+, 861.0028 [M+7H] 7+. 
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Figure 3.21 ESI-MS spectra of pyrene-2-Q calculated mass for C257H316N110O70: 
1214.2150 [M+5H] 5+, 1012.0138 [M+6H] 6+, 867.5844 [M+7H] 7+. 
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Figure 3.22 ESI-MS spectra of Fluorescein-2-Q calculated mass for C263H321N111O76: 
1043.1987 [M+6H] 6+, 894.3143 [M+7H] 7+. 
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Figure 3.23 HPLC-UV absorption spectrum of pyrene-1-Q at 265 nm. 
 
Figure 3.24 HPLC-UV absorption spectrum of acridone-1-Q at 265 nm. 
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Figure 3.25 HPLC-UV absorption spectrum of acridine-1-Q at 265 nm. 
 
Figure 3.26 HPLC-UV absorption spectrum of Fluorescein-1-Q at 265 nm. 
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Figure 3.27 HPLC-UV absorption spectrum of pyrene-2-Q at 265 nm. 
 
Figure 3.28 HPLC-UV absorption spectrum of Fluorescein-2-Q at 265 nm. 
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13. CHAPTER IV: SYNTHESIS OF A (Gd(III)-DOTA)4-PNA 
CONJUGATE AS A CONTRAST AGENT FOR MR IMAGING 
A manuscript of this chapter is in preparation for submission. Xiaoxiao Wang, Mark Milne, 
Francisco Martínez, Timothy J. Scholl and Robert H. E. Hudson*, Synthesis of a 
Poly(Gd(III)-DOTA)-PNA Conjugate as a Potential MRI Contrast Agent via Post-
Synthetic Click Chemistry Functionalization. 
4.1 Introduction 
Molecular imaging has been employed in clinical medicine for the past decades by using 
modalities such as magnetic resonance imaging (MRI), single photon emission 
tomography (SPECT)/positron emission tomography (PET) and optical imaging. Although 
SPECT/PET is very sensitive, the requirement of radioactive agents limits its application. 
SPECT/PET is only used when suspect masses are evident or highly likely due to the 
potential risks of radioisotope exposure. Optical imaging has been widely employed, but 
disadvantages such as low efficiency of light transmission through tissues and difficult 
quantification, cannot be neglected.1 Therefore, by comparison, MRI is an attractive 
alternative for molecular imaging because it is non-invasive, does not require exposure to 
radiation and provides three-dimensional images with high spatial resolution and high 
contrast. After the introduction of MRI in the clinic in 1980s, it has shown unparalleled 
power in diagnostic medicine, especially for the detection and characterization of diseased 
soft tissues such as solid tumors.  
The quality of MR images, including spatial resolution, signal-to-noise and contrast-to-
noise ratios (SNR and CNR), has been substantially improved in the past years owing to 
the use of higher magnetic fields and the development of safe and effective MRI contrast 
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agents (CAs). MRI CAs are biocompatible magnetic materials that alter the longitudinal 
(T1) and transverse (T2) relaxation rates of the surrounding water protons, therefore 
enhancing image contrast in tissues of interest. They are generally categorized as T1 and T2 
CAs based on their magnetic properties and relaxation mechanisms. CAs have become 
essential for improving the image quality by increasing the image contrast between normal 
and diseased tissues.2–5 Gadolinium [Gd(III)] chelates could increase T1 relaxation rate 
(1/T1) and have been commonly used as T1 CAs by generating a positive image contrast. 
Superparamagnetic iron oxide nanoparticles have been found more effective for increasing 
T2 relaxation rate (1/T2), thus commonly used as T2 CA, which produces negative image 
contrast. To date, the majority of MRI CAs used in clinical practice are Gd(III) chelates 
(Figure 4.1), with over 10 million contrast enhanced MRI scans on an annual basis, because 
of their high paramagnetism, favorable properties in term of relaxation enhancement, 
relatively high stability, and tolerance in the body. 
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Figure 4.1 Some of the Gd(III)-based MRI contrast agents currently used in the clinical 
practice55 (copyright 2013 John Wiley and Sons). 
Biocompatibility of the MRI CA is an important consideration for clinical applications. 
Gd(III) ions are highly toxic in ionic form, acutely interfering with calcium channels and 
protein-binding sites.6,7 Free Gd ions accumulate in the liver, spleen, kidney and bones and 
have an LD50 = 0.2 mmol-1kg-1 in mice. To overcome this issue, Gd(III) ions are generally 
complexed with chelating ligands to prevent tissue interaction and minimize toxic side 
effects. Nevertheless, toxic Gd(III) ions may still be released from some of the chelates by 
exchange with ions such as Zn2+, Ca2+, and Cu2+ in the body and by protonation of the 
ligands at low pH that may cause chelate dissociation in vivo.8,9 A serious adverse reaction 
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called nephrogenic systemic fibrosis may be associated to the use of Gd(III)-based CA in 
a very small percentage of patients with renal malfunctions due to incomplete excretion 
and possibly chelate disassociation of the agents.10 The US Food and Drug Administration 
(FDA) has issued a black box warning to prohibit the use of Gd(III)-based CA in the 
patients with renal malfunctions. Therefore, safer Gd(III) chelate-based MRI CAs are 
required. The CAs need to be excreted after the contrast-enhanced MRI within hours. 
Moreover, small Gd(III) chelates have a relatively low relaxivity and extravasate non-
selectively from blood into the interstitium of both normal tissue and tumor, which has 
been a major limitation for their clinical applications. Therefore, macromolecular Gd(III) 
complexes have been proposed with higher relaxivity and prolonged retention in blood 
circulation. It has been demonstrated that attaching Gd(III) chelates to macromolecules 
slows down the rotational motion of the complexes, thus increaseing relaxivities.11 
Macromolecular Gd(III) chelates have relatively higher relaxivity (r1) per Gd(III) ion than 
that of small molecular Gd(III) chelates. For example, Gd-DTPA conjugated to polylysine 
(PLL) with the molecular weights ranging from 3.3 up to 102 kDa has a r1 per Gd(III) ion 
2.5 times higher than that of Gd-DTPA (measure at 2.4 T).12 P792 (Vistarem), a 
macromolecular Gd-DOTA derivative (Figure 4.2), has a r1 relaxivity as high as 39 mM-
1second-1 per Gd(III) ion (0.47 T, 37 oC, in water) whereas r1 is 3.4 mM-1second-1 for Gd-
DOTA (0.47 T, 37 oC, in water).12,13 Higher relaxivity of macromolecular Gd(III) 
complexes can help generate more efficient contrast enhancement. Thus they can be used 
at significantly reduced doses. On the other hand, macromolecular CAs could effectively 
target clinically important targets like DNA, mRNA or proteins/enzymes. For example, 
targeted delivery of CAs into tumor tissues is crucial in cancer diagnostic MRI, because 
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tumors are physiologically different from normal tissues and have leaky blood vasculature. 
Tumor tissues usually abundantly express cancer-related biomarkers on cell surface, 
extracellular matrix and angiogenic microvessels, which would be ideal targets for 
molecular imaging. Therefore, ligands with high-binding affinity are essential for the 
design of targeting CA in order to generate sufficient contrast enhancement of visualizing 
these biomarkers with the aid of MRI. 
 
Figure 4.2 Examples of macromolecule-based Gd(III) contrast agents55 (copyright 2013 
John Wiley and Sons). 
The 3’-ends of all fully processed eukaryotic mRNAs except most histone genes have a 
polyadenylic acid [poly(rA)] tail. It consists of 200-250 adenine bases and occupies a 
116 
 
significant role for mRNA stability, translation and transport.14–16 Poly(rA) tail has also 
been recognized as a contributor in increasing length and as a platform to recruit mRNA 
export factors.17 Polyadenylation of mRNA is a critical cellular event in the transcription 
process for the maturation of all eukaryotic mRNAs. It is catalyzed by the enzyme poly(rA) 
polymerase (PAP). Neo-PAP, a recently identified human poly(rA) polymerase, is 
significantly over-expressed in human cancer cells in comparison to its expression in 
normal or virally transformed cells, and may represent a tumor-specific target.18,19 This 
suggests the poly(rA) tail acts as a potential malignancy specific target for the development 
of hybridization probes.20 Probes that can recognize and bind to the poly(rA) tail of mRNA 
might interfere with the full processing of mRNA by PAP and switch off protein synthesis. 
Some small molecules like protoberberine alkaloids have been found to bind to poly(rA) 
with high affinity leading to self-structure formation. Self-structure formation is very 
significant with respect to its biological importance.20–22 On the other hand, it would be 
interesting to apply antisense agents to binding poly(rA), blocking transcriptional 
elongation and inhibiting the binding of transcriptional factors. Unlike regular antisense 
DNA/RNAs, PNA with high affinity, specificity and stability, would have great potential 
as a binder of poly(rA). It is also resistant to degradation in biological fluids as it is not 
recognized by nucleases or proteases. It has been proven that a PNA probe could efficiently 
recognize and bind to the poly(rA) tail.23 However, the studies using PNA as a 
hybridization probe targeting poly(rA) via MRI has not been disclosed yet. Therefore, it 
would be interesting to know if Gd(III)-chelated PNA would be a useful poly(rA)-targeted 
CA.  
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Macromolecular MRI CA are mainly prepared by conjugating Gd-DOTA and Gd-DTPA 
to biocompatible macromolecules. Various bifunctional chelates of DTPA and DOTA have 
been developed with attachments such as anhydride, N-hydroxysuccinimide activated 
carboxylic acid, maleimide, alkynyl, and azide for conjugation. Bifunctional ligands and 
small molecular Gd(III) chelates can be readily attached to high-molecular-weight 
macromolecules including proteins,24 polymers,25 self-assembled peptide amphiphile 
nanofibers26 and oligonucleotides27. The structures of some macromolecular Gd(III)-based 
CAs are shown in Figure 4.2. Generally, there are two main strategies for labelling of PNA 
with Gd(III) chelates. One of them is adding a Gd(III)-DOTA-containing monomer to the 
sequence during solid-phase synthesis. For example, a Fmoc-Lys(DOTA)-OH has been 
synthesized and inserted into PNA via solid-phase peptide synthesis.28 The imaging radio-
metal was chelated to the resulting PNA-DOTA. This type of labelling method has obvious 
drawbacks, such as laborious and time-consuming synthesis of modified PNA monomers 
and low yield of the coupling of the modified monomer due to potential incompatibility 
with the chemical conditions (acidic or basic) of SPPS. Hence, the other strategy via post-
synthetic labelling either in solution or on the solid-phase resin has been attempted. For 
example, as Wickstrom reported, DOTA-(t-OBu)3COOH was coupled to the amino groups 
of PNA oligomer on solid-phase followed by cleavage and Gd chelation.29 However, this 
procedure is still tedious and includes deprotection, activation, coupling, capping, 
deprotection again and Gd chelation. Also, protection of DOTA-COOH by t-OBu is 
required in this study to avoid side reactions as carboxylic group would participate in the 
coupling step. Therefore, an approach that is chemically selective, robust to functionalities 
on PNA and operationally easy is still needed. With the inspiration by our previous work 
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on post-synthetic click chemistry for functionalization of PNA,30 a labelling strategy 
utilizing copper-catalysed click chemistry on polymer supported targets has been pursued. 
Although most of PNA-CuAAC approaches were performed in solution, our attention 
stayed on on-resin CuAAC, because it combines advantages of click chemistry and SPPS 
in which an excess of reactants can be used and easily washed away from the solid support 
without tedious workup; it is operationally easy to perform, and often to give quantitative 
yields. On the other hand, post-synthetic functionalization of the PNA oligomer represents 
a viable alternative to potentially reduce the overall synthetic effort, as well as introducing 
a step that is amenable to structural diversification. To apply on-resin CuAAC to post-
synthetically functionalize PNA, an Fmoc-azide PNA monomer in which a nucleobase was 
replaced with an azide group has been synthesized.21 Up to four azide monomers have been 
coupled into a PNA sequence by automated SPPS in different positions without any 
concern for incompatibility. 
Accumulation of Gd-containing probes at the target site is usually a main concern owing 
to the limited concentration of the specific mRNAs in cancer cells. This has been addressed 
in Wickstrom’s study in which multiple Gd chelators have been conjugated to PNA-peptide 
dendrimer.29,31 In this way, the number of chelated Gd(III) ions per hybridization probe has 
been increased. In this way, the number of chelated Gd(III) ions per hybridization probe 
was increased by conjugation of PNA to a dendrimer labelled with Gd(III) chelators. They 
demonstrated that the relaxivity per probe rose as the number of Gd(III) per probe rose.  
To develop an effective PNA probe as a potential MRI contrast agent that can recognize 
and bind to poly(rA), a hybridization probe, (Gd(III)-DOTA)4-PNA was designed and 
synthesized in this work. Unlike a dendrimer-shape PNA-Gd probe, this probe is a comb-
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shape PNA with four Gd chelators. It could bind to long Poly(rA) tail and form a triplex 
structure, which could also concentrate Gd ions by taking advantage of the target sequence 
(Figure 4.3), thus enhancing the contrast of MR images.  The limitations such as tedious 
work up and low yield of traditional approach that requires complicated protection strategy 
for conjugation of PNA with Gd chelators, cannot be neglected. Therefore, a method based 
on on-resin click chemistry is described in this chapter. A PNA sequence including four 
azide monomers and ten thymine residues targeting poly(rA) tail was first synthesised.32–
34 Alkynyl-(Gd(III)-DOTA) molecules could be “clicked” to the PNA oligomer via on-
resin CuAAC to yield the hybridization probe, (Gd(III)-DOTA)4-PNA, which was 
successfully characterized and evaluated. 
 
Figure 4.3 Conceptual scheme of preparation and application of (Gd(III)-DOTA)4-PNA. 
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4.2 Results and discussion 
In order to optimize the derivatization chemistry, a test sequence, Fmoc-TTT-Az-K 
(PNA1), containing one azide unit (Az, Scheme 4.1) was first synthesized. Without 
purification, the crude resin-bound PNA1 was placed in a peptide vessel. Alkynyl-(Gd(III)-
DOTA)35–37 (30 equiv.), CuSO4·5H2O (60 equiv.), sodium ascorbate (240 equiv.), and the 
ligand N,N’-dimethylethylenediamine (DMEDA) (60 equiv.) were added and 
isopropanol/H2O(1:2, v/v) was used as the solvent. After the resin was shaken at room 
temperature (12 h), Gd(III)-DOTA was found to be successfully attached to PNA1 with no 
underivatized PNA1 being detected by LC/MS methods.  The ESI-MS analysis showed 
amass of 973.4175 [M+2H]2+ and 648.9204 [M+3H]3+ which were consistent with the 
calculated mass of 973.5574 [M+2H]2+ and 649.3742 [M+3H]3+. We then proceeded to 
prepare a PNA containing four azide monomers, PNA2 (Fmoc-K-Az-β-Az-β-Az-β-Az-K-
TTTTTTTTTT-K) by using regular PNA T monomers, Fmoc-Lys(Boc)-OH, Fmoc-β-Ala-
OH and Fmoc azide monomer (Scheme 4.1). A small portion of PNA was cleaved off the 
resin and characterization was performed by reversed phase HPLC and ESI-HRMS. The 
m/z of 1411.6052 [M+3H]3+ and 1058.9668 [M+4H]4+ agree well with the calculated m/z 
of 1411.7679 [M+3H]3+ and 1059.0779 [M+4H]4+. Without purification, the resin-bound 
PNA2 was subjected to CuAAC in the presence of excess alkynyl-(Gd(III)-DOTA) 
(Scheme 4.1). By using this approach, Fmoc(Gd(III)-DOTA)4-PNA conjugate (Fmoc-K-
Gd-β-Gd-β-Gd-β-Gd-K-TTTTTTTTTT-K) has been successfully synthesised with 
quantitative conjugation yields via on-resin CuAAC. The excess reagents, solvents, and 
catalyst were easily washed from the resin, whereas the workup to remove these materials 
using solution phase methods can be laborious in our experience. ESI-HRMS of 
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Fmoc(Gd(III)-DOTA)4-PNA conjugate showed 1324.0796 [M+5H]5+ and 1103.4063 
[M+6H]6+ which are in accordance with the calculated mass of 1324.0326 [M+5H]5+ and 
1103.5285 [M+6H]6+. After Fmoc deprotection and cleavage of the oligomer from the resin, 
only the usual reversed phase HPLC purification was required. MS results of (Gd(III)-
DOTA)4-PNA (K-Gd-β-Gd-β-Gd-β-Gd-K-TTTTTTTTTT-K) showed 914.5258 
[M+7H]7+ and 710.6509 [M+9H]9+ corresponding to the calculated mass of 914.2765 
[M+7H]7+ and 711.3279 [M+9H]9+. 
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Scheme 4.1 Synthesis of (Gd(III)-DOTA)4-PNA by on-resin CuAAC. a) alkynyl-
(Gd(III)-DOTA) (30 equiv.), CuSO4·5H2O (60 equiv.), sodium ascorbate (240 equiv.), 
DMEDA (120 equiv.), isopropanol/H2O(1:2, v/v), RT, overnight; b) TFA/TES (95:5, v/v). 
To determine the stoichiometry of the binding of (Gd(III)-DOTA)4-PNA conjugate with 
poly(rA), Job plots from UV-vis data were constructed and DNA-A10 was used as the 
counterpart of (Gd(III)-DOTA)4-PNA. The results were obtained at two wavelengths (260 
and 283 nm)24 (Figure 4.4). They indicated a binding stoichiometry of about 2 : 1 for 
(Gd(III)-DOTA)4-PNA:DNA-dA10 complexes, which demonstrated the formation of 
[(Gd(III)- DOTA)4-PNA]2 : DNA triplexes.33 Moreover, as the triplex formation of (PNA-
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T8)2: poly(rA40) has been reported,32 we believe that (Gd(III)-DOTA)4-PNA would form a 
triplex with poly(rA) with stoichiometry of 2:1.  
 
Figure 4.4 Job plot of dA10 (4 µM/strand) and (Gd(III)-DOTA)4-PNA (4 µM/strand) 
mixtures in the molar ratios of 0:100, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 
80:20, 90:10. Solution conditions: 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 
7, 25 oC. 
Thermal studies were performed by UV-melting in the presence of 2 µM [(Gd(III)-
DOTA)4-PNA]2 : poly(rA). Urea was used as chaotropic agent because the triplex was 
found to be too stable to measure.38 The melting curves illustrates a biphasic profile with 
Tm values of 56 oC and 85 oC in the presence of 6 M urea (Supplementary Information, 
Figure 4.8), indicating the existence of triplex, which is also demonstrated by the Job plot 
studies. Experiments were repeated thrice and the Tm values were measured from the first 
derivative plots.  
To evaluate our (Gd(III)-DOTA)4-PNA probe, we acquired its NMRD profiles at a series 
of temperatures. A value of 5.6 mM-1s-1 is observed at 20 MHz and 25 oC per Gd ion (Figure 
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4.6). NMRD profile of the triplex, [(Gd(III)-DOTA)4-PNA]2 : Poly(rA), has also been 
achieved at 25 oC with r1 of 6.6 mM-1s-1 at 20 MHz. These findings are in good agreement 
with other DO3A monoamide compounds (4-5 mM-1s-1) under similar conditions.39 
Evaluation over the entire profile gives some indication of the solution structure of our 
probe. An increase in relaxivity is seen at ~20 MHz for both (Gd(III)-DOTA)4-PNA and 
the triplex, [(Gd(III)-DOTA)4-PNA]2 : Poly(rA) at 298K. This increase has been attributed 
to the slowing of rotation,40 possibly due to the aggregation of the (Gd(III)-DOTA)4-PNA 
and to a lesser extent the triplex formation in the presence of poly(rA).  This is further seen 
in the temperature studies where the increase in relaxivity at 20 MHz is not present for 
higher temperatures, most likely due to the unfolding of the aggregate or destabilization of 
the triplex formation (supplemental information). It is also noteworthy that triplex 
formation of this probe with a poly(rA) tail would deliver 160–200 Gd3+ ions to a localized 
microenvironment compared with dendrimeric developed contrast agents that have 
achieved a loading of 150-200 chelators using a generation 6 PAMAM dendrimers. 41 
While there are 256 potential sites available in a G6 PAMAM dendrimer, a typical loading 
would be ~170 Gd3+ ions per dendrimer. Other dendrimers up to G10 have been 
synthesised with a loading of 1860 Gd3+ ions.42 However, all these structures lack the 
specificity that is necessary for molecular MRI and incorporation of molecules such as 
polysaccharides,43–46 oligopeptides,47–50 proteins,47,51 antibodies52 and oligonucleotides53 is 
needed. In comparison, our (Gd(III)-DOTA)4-PNA probe not only consists of targeting 
oligomer, but also concentrate and deliver a high load of Gd ions. 
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Figure 4.5 Longitudinal relaxivity (r1) of [(Gd(III)-DOTA)4-PNA]2:Poly(rA) triplex and 
control linear (Gd(III)-DOTA)4-PNA with a constant 0.13 mM Gd(III) in 100 mM NaCl, 
10 mM NaH2PO4, 0.1 mM EDTA, 6 M urea, pH 7, 25 oC. 
4.3 Conclusions 
In summary, a poly(Gd(III)-DOTA)-PNA probe has been prepared via on-resin click 
chemistry, which is robust, operationally convenient and efficient for conjugation of PNA 
with Gd chelators. The resulting PNA oligomer could recognize poly(rA) tail of mRNA 
and form a stable triplex. The probe and its triplex with poly(rA) have been evaluated by 
NMRD studies. An increase in relaxivity is seen at 20MHz for the triplex, [(Gd(III)-
DOTA)4-PNA]2 : Poly(rA) at 25 oC compared with (Gd(III)-DOTA)4-PNA. The 
relaxivity of (Gd(III)-DOTA)4-PNA at 38 oC (~4.2 mM−1s−1) is comparable to the clinical 
agents Magnevist® (gadopentetate dimeglumine, Gd-DTPA), Dotarem® (gadoterate, Gd-
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DOTA), Prohance® (gadoteridol, Gd(HP-DO3A)) and Omniscan® (gadodiamide, 
Gd(DTPA-BMA)) (3.5-3.8 mM−1s−1 at 20 MHz and 37 °C). By binding to poly(rA), Gd 
ions would be significantly loaded to a localized microenvironment, which may improve 
the enhancement of contrast in MR images.    
4.4 Experimental  
All chemicals and solvents were used as received unless specified. All solvents were 
peptide synthesis grade, except water (18.2 MΩ⋅cm-1). The “Fmoc-azide monomer” was 
prepared according to previously reported protocols.38 All reagents for synthesis of PNAs 
were commercially available.  
 
Synthesis of PNA1 
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide 
synthesizer. PEGA-Lys(Boc)-Fmoc resin (loading 0.113 mmol/g) were used as the solid 
support. The synthesis was terminated retaining the terminal Fmoc protecting group. A 
small portion of the resin was taken for characterization and the oligomer was 
cleaved/deprotected under standard conditions for the characterization of PNAs by ESI-
MS. Other portions of the resin were taken and manipulated in manual peptide vessels. 
 
General procedure for on-resin click chemistry 
Alkynyl-(Gd(III)-DOTA) (30 equiv.) in isopropanol (0.5 mL), CuSO4·5H2O (60 equiv.) 
in H2O (0.33 mL), sodium ascorbate (120 equiv.) in H2O (0.33 mL), and N,N’-
dimethylethylenediamine (DMEDA) (60 equiv.) in H2O (0.33 mL) were added to the resin 
in a peptide vessel. The resin was shaken at room temperature under N2 overnight. After 
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the reaction was deemed completed by ESI-MS, the solvent was drained and the resin was 
washed sequentially with DMF, DCM, H2O, MeOH and finally DCM. Then PNA was 
cleaved from the resin, purified and characterized following by our previously reported 
procedure.54 
The crude poly(Gd(III)-DOTA)-PNA probe purified by reversed phase HPLC at 50 oC on 
a 250 × 4.6 mm VARIAN C18 column eluted with a gradient of 0-5 min, 1% MeCN, 5-20 
min, linear from 1% to 60% MeCN, 20-35 min, linear from 60% to 100% MeCN and 35-
40 min, linear from 100% MeCN to 100% H2O. Both H2O and MeCN solvents contain 
0.05% TFA. 
 
UPLC/Mass Spectroscopy of PNA oligomers 
Ultra-performance liquid chromatography (UPLC) was performed using a BEH C18 
column (particle size 1.7 µm; 1.0 i.d.×100 mm), Waters LCT Premier high-resolution 
electrospray ionization mass spectroscopy (HR-ESI-MS) and diode array UV detectors. 
The mobile phase was 100% H2O to 100% MeCN over 5 min by linear gradient, and 100% 
MeCN over 2 min, at flow rate 0.1 mL/min. Both solvents contain 0.1% HCOOH. 
 
Quantification of oligomers 
UV-visible spectrophotometer was used to determine the concentrations of oligomer 
solutions. The absorbance at 258 nm and 260 nm of the samples were measured for poly(rA) 
and PNA, respectively. 9800 M-1cm-1 was used as ε258 of each nucleobase on poly(rA). The 
equation below was used for calculating the concentration of nucleobases of poly(rA). 
c (µM)=
1000×A258
 9.8  
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8800 M-1cm-1 were used as ε260 values of T. The equation below was used for calculating 
the concentration of nucleobases of poly(Gd(III)-DOTA)-PNA.  
c (µM)=
1000×A260
 8.8  
 
 
Thermal denaturation experiments of oligomers 
UV melting experiments were carried out to measure the Tm values of oligomers in this 
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM 
EDTA, pH 7.0. Samples at 2 µM concentration were heated to 95 ºC, cooled to room 
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed 
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average 
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ± 
0.5 ºC. Tm values were estimated for cooperative transitions by the first derivative method. 
Temperature dependent UV spectra that lacked upper and lower baselines, lacked 
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were 
deemed not be to cooperative transitions. 
 
General procedure for drawing Job plot by UV–vis method 
A series solutions containing (Gd(III)-DOTA)4-PNA and dA10 in the ratios of 0:100, 
10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10 and 100:0, respectively, were 
prepared with the concentration of 4 µM at pH 7.0 in the condition of 100 mM NaCl, 10 
mM Na2HPO4, 0.1 mM EDTA, pH 7.0. The absorbances at 260 nm and 283 nm were 
plotted against the percentage of (Gd(III)-DOTA)4-PNA. 
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Nuclear Magnetic Relaxation Dispersion (NMRD) studies of single strand, (Gd(III)-
DOTA)4-PNA and the triplex, [(Gd(III)-DOTA)4-PNA]2:Poly(rA)  
The T1 NMRD profiles of 1 mL samples were acquired with a fast field-cycling NMR 
relaxometer (SpinMaster FFC2000 1T C/DC, Stelar, s.r.l. Mede, Pavia (PV) - Italy). All 
experiments were acquired with controlled temperatures (25, 38, 60 and 80 °C) and 
changing the relaxation field in 30 steps, logarithmically distributed from 0.01 to 42.485 
MHz (0.23 mT up to 1 T) and using an acquisition field of 16.2 MHz. The quantitative 
relaxivity (r1) values were normalized to the reported gadolinium concentration for each 
sample. 
4.5 Supplementary Information 
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Scheme 4.2 Synthesis of Gd(III)-DOTA-PNA1 by on-resin CuAAC. a) alkynyl-(Gd(III)-
DOTA) (7.5 equiv.), CuSO4·5H2O (15 equiv.), sodium ascorbate (30 equiv.), N,N’-
dimethylethylenediamine (DMEDA) (15 equiv.), isopropanol/H2O (1:2, v/v), r.t.; b) 
TFA/TES (95:5, v/v). 
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Figure 4.6 ESI-MS spectrum of PNA1 calculated mass for C79H104GdN25O24: 973.5574 
[M+2H]2+. 
 
Figure 4.7 ESI-MS spectrum of PNA2, calculated mass for C176H240N70O56: 1411.7679 
[M+3H]3+, 1059.0779 [M+4H]4+. 
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Figure 4.8 ESI-MS spectrum of Fmoc(Gd(III)-DOTA)4-PNA, calculated mass for 
C252H352Gd4N90O84: 1324.0326 [M+5H]5+, 1103.5285 [M+6H]6+. 
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Figure 4.9 HPLC-UV absorption spectrum of purified (Gd(III)-DOTA)4-PNA) (top) 
and ESI-MS spectrum of (Gd(III)-DOTA)4-PNA) (bottom), calculated mass for 
C237H342Gd4N90O82: 914.2765 [[M+7H]7+, 711.3279 [M+9H]9+. 
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Figure 4.10 First derivative UV melting plots of [(Gd(III)-DOTA)4-PNA]2:poly(rA) at 
260 nm at a concentration of 2 µM. conditions: 100 mM NaCl, 10 mM NaH2PO4, 0.1 mm 
EDTA, 6 M urea, pH 7, 25 oC. 
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Figure 4.11 NMRD profiles of (Gd(III)-DOTA)4-PNA at 25, 38, 60 and 80 oC. conditions: 
100 mM NaCl, 10 mM NaH2PO4, 0.1 mm EDTA, 6 M urea, pH 7, 25 oC. 
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15. CHAPTER V: BIOCONJUGATION OF OLIGOPEPTIDE TO 
GOLD NANOPARTICLES FOR CT IMAGING VIA STRAIN-
PROMOTED AZIDE-ALKYNE CYCLOADDITION (SPAAC) 
Chapter 5 has been published as a research paper, and it is reprinted (adapted) with 
permission from Xiaoxiao Wang, Pierangelo Gobbo, Mojmir Suchy, Mark S. Workentin* 
and Robert H. E. Hudson*, RSC Advances, 2014, 4, 43087-43091. Copyright 2014 Royal 
Society of Chemistry. 
5.1 Introduction to gold nanoparticles and targeted CT imaging 
Gold in its bulk scale is a popular material and has been widely used in jewelry, coinage, 
and electronics. Gold has been found of great help in applications ranging from catalysts1–
3 to anti-arthritic medications.4 Unlike bulk- or molecular-scale gold, gold nanoparticles 
(AuNPs) exhibit unique properties due to their size.5 The word nano describes any material 
or property with dimensions on the nanometre scale (1-100 nm). In 2012, Dreaden and 
coworkers have summarized AuNPs of various sizes and shapes with potential applications 
in biomedicine.6 They could preferentially accumulate at tumor or inflammation sites and 
enter cells through different but faster pathways than small molecules. Due to their facile 
surface chemistry, AuNPs loaded with binding ligands can be used as artificial antibodies. 
Their binding affinity can be precisely tuned by varying the density of binding ligands on 
the surfaces. AuNPs can also efficiently convert light into heat, so they would lead to highly 
specific thermal ablation of diseased or infected tissues. Multivalency of gold enables 
AuNPs to shield unstable drugs or poorly soluble imaging contrast agents (CAs) and to 
facilitate effective delivery to otherwise inaccessible regions of the body. Because of the 
greater number of electrons of gold, AuNPs attenuate X-rays more effectively than iodine-
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based CAs and therefore produces superior contrast for diagnostic computed tomography 
(CT) scans. More importantly, it is possible that all of the above-mentioned advantages of 
gold nanoparticles can be chemically combined into one construct allowing for 
simultaneous targeting, diagnostic, and therapeutic functionalities which are helpful for a 
particular patient or a disease.5  
CT has become one of the most widespread molecular imaging technologies due to its high 
sensitivity and spatial resolution, cost effectiveness, deep penetration capability, and facile 
three-dimensional imaging reconstruction technique.7,8 To obtain high-quality CT imaging 
of soft tissues, CAs are usually required such as iodine-based small molecules. However, 
their disadvantages like short imaging time due to their fast clearance by kidney, renal 
toxicity at a relatively high concentration,9 and especially non-specificity cannot be 
neglected. Therefore, it is essential to develop novel targeted CT contrast agents to 
overcome these shortcomings.  
Nanoscale CAs for CT imaging have become extremely attractive thanks to the 
development of nanotechnology. Various nanoparticles-based CAs, such as bismuth 
sulfide nanoparticles,10–13 lanthanide-doped BaYbF5 upconversion nanoprobes,14 
lutetium-based nanoparticulate CAs,15 ytterbium-based NPs,16,17 tantalum oxide NPs,18 and 
AuNPs,19 have been employed for targeted CT imaging of different biological systems. 
Among the diverse types of nanoscale CT CAs, AuNPs have been given considerable 
attention owing to their better X-ray attenuation than iodinated CT contrast agents, 
chemical stability, and good biocompatibility after surface functionalization.8,20–23 
In 1971, Faulk and Taylor reported a technique to conjugate antibodies with colloidal gold 
for direct electron microscopic visualization of Salmonella surface antigens.24 From then 
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on, functionalized AuNPs have been extensively investigated in the fields of diagnostics, 
bioimaging, drug and gene delivery, immunology and plasmonic biosensors.6,25–28 The 
success of AuNPs in these fields has led to the Food and Drug Administration (FDA) 
approval for AuNP-based in vitro diagnostic systems in clinical trials for cancer 
treatments.29 To develop effective systems for targeted cancer diagnosis and therapies, it is 
necessary to functionalize AuNPs with biomolecules such as DNA, proteins and peptides. 
Peptide-AuNP conjugates have been exploited recently as CAs and nanocarriers in targeted 
imaging for early stage cancer diagnosis and in the pharmaceutical field for targeted 
intracellular drug/gene delivery, respectively.27,30  
Thus our attention has been turned to the development of targeted CT CAs via 
functionalization of AuNP with PNA or oligopeptides which would be a good start. The 
main challenge of conjugation of peptides to AuNPs lies in understanding and controlling 
the interfacial chemistry between the peptide and the nanomaterial surface on the molecular 
scale. The reported strategies for bioconjugation of AuNPs with peptides include sulphur-
gold bond formation by the direct reaction of cysteine-terminated peptides with the gold 
surface and electrostatic interactions between a particle and peptides that have been 
coupled to bovine serum albumin (BSA).31 Although the first method is operationally easy 
to perform, it is difficult to achieve a high degree of substitution. AuNP bioconjugation via 
electrostatic interactions has good stability in aqueous solution, but the layer-by-layer 
assembly results in large hydrodynamic radii of nanoparticles, which limits their 
application under certain conditions, and offers poor control over the degree of 
functionalization. Alternatively, a strategy via amide bonds formation involving a water-
soluble carbodiimide, N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
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(EDC), was developed for bioconjugation of AuNPs. Carboxylic groups can be activated 
by EDC and reacted with primary amines through a condensation reaction to yield amide 
bonds. Moreover, sulfo-NHS (N-hydroxy sulfosuccinimide) is used to increase the stability 
of active intermediates in coupling reactions via the formation of active ester functional 
groups with carboxylates. EDC/NHS coupling has been widely used in preparation of 
AuNP-peptide conjugates.32 However, this method is still a challenge as quite often, the 
peptides do not couple efficiently to AuNPs.33,34 Additionally, EDC/NHS coupling method 
is not very selective as it involves the reaction between an amine and carboxylic acid 
groups, which widely exist in peptides.35 
In order to overcome the aforementioned difficulties, recent effort has focused on the use 
of “click chemistry” for conjugation of AuNPs with biomolecules.33 For example, the 
copper-catalyzed azide-alkyne cycloaddition (CuAAC) has been utilized to conjugate large 
azido-containing AuNPs with alkyne functionalized horseradish peroxidase (HRP).34 
However, the requirement of using copper ion as catalyst complicates the reaction and 
could increase in vivo biological toxicity. The strain-promoted azide-alkyne cycloaddition 
(SPAAC), also known as Cu-free alkyne-azide cycloaddition, can be used to overcome 
these problems. The SPAAC reaction has been developed as a powerful bioconjugation 
tool that displays outstanding chemoselectivity, excellent biocompatibility and takes place 
under very mild reaction conditions. Since its first development,36 much effort has been 
directed toward the synthesis of cycloalkynes with increased ring strain (to accelerate the 
reaction) and higher hydrophilic character (for in vivo applications). The challenge behind 
the syntheses of these interesting molecules relies on finding the right balance between 
reactivity and chemoselectivity. Indeed, the greater the ring strain, the more susceptible the 
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triple bond is to nucleophilic attack (i.e., addition reactions or rearrangement of 
cyclooctynes) thus lowering the chemoselectivity towards the cycloaddition with an azide. 
For example, it has been reported that highly strained biarylazacyclooctynone and 
analogous bioconjugation reagents undergo rearrangement and addition reactions leading 
to tetracyclic products.37 The rate of rearrangement was found to be accelerated as the 
concentration of acid increased. This is problematic because concentrated TFA, such as 95% 
TFA with scavengers, is the typical reagent for cleavage of peptides from solid supports 
like Wang resin, Rink Amide resin, etc. together with the removal of the side chain 
protecting groups. This limits the applications of strained alkynes for preparation of 
clickable peptides. Additionally, strained alkynes have been shown to undergo side 
reactions with cellular cysteines and other nucleophilic residues.38,39 However, 
nucleophilic side chain functionalities, such as hydroxyl (Tyr, Ser, Thr), amino (Lys), 
guanidine (Arg) or sulfhydryl (Cys), widely exist in bioactive peptides and may react with 
highly reactive cyclooctynes through a nucleophilic attack.40 This also limits the 
application of SPAAC. Interestingly, the application of interfacial SPAAC for 
bioconjugation of AuNPs with peptides had not yet been disclosed prior to the work 
described herein.  
In this chapter, the development of a novel general method for the synthesis of AuNP-
peptide bioconjugates is described that takes into account the side reactivity of the strained 
alkynes and therefore combines an interfacial SPAAC with a post assembly deprotection 
(PAD) for the conjugation of dibenzocyclooctyne (DBCO)-oligopeptides to small, water-
soluble azide-AuNPs. It is shown that how this approach overcomes the aforementioned 
drawbacks and extends the application of SPAAC to the bioconjugation of metallic 
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nanoparticles in a quick, reliable and facile way. Importantly, the undesired side reactions 
of the strained alkyne in the presence of concentrated TFA and with nucleophilic sites on 
peptides are avoided through mild cleavage condition and retention of side-chain protecting 
groups on the peptides during the SPAAC reaction. The protecting groups can then be 
easily removed, i.e. post assembly deprotection (PAD), under reaction conditions that 
preserve the integrity of the gold core, and the AuNP bioconjugate can be easily purified 
by dialysis. Finally, the amount of conjugated peptide can be easily calculated. 
5.2 Results and discussion 
To showcase this SPAAC-PAD strategy an azide-AuNPs based on tri- and tetra-ethylene 
glycol ligands that impart both water- and organic solvent-solubility to final AuNPs was 
used. This is useful for manipulating the AuNP in organic solvents to facilitate both the 
SPAAC reaction and the deprotection reaction, as well as maintaining solubility in water 
for further in vivo applications. 
The azide-AuNPs were prepared and characterized following our previously reported 
procedure.41 Briefly, triethylene glycolmonomethyl ether AuNP (Me-EG3-AuNP) with a 
gold core diameter of 3 ± 0.5 nm were synthesized via a modified Brust-Schiffrin method. 
The azide ligand N3-EG4-SH was synthesized and introduced onto the surface of Me-EG3-
AuNP using a place-exchange reaction. In a typical synthesis 42.5 mmol of N3-EG4-SH 
were stirred for 20 minutes in acetone and in presence of 50 mg of Me-EG3-AuNP. 
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Figure 5.1 IR spectrum of azide AuNPs. 
The free thiols were subsequently removed by trituration of the dried AuNP film first with 
hexanes and followed by isopropanol. Azide-AuNPs were characterized by 
thermogravimetric analysis (TGA), transmission electron microscopy (TEM) and FT-IR 
spectroscopy. The IR spectrum of resulting AuNPs showed the appearance of asymmetrical 
stretching of the azide group at 2110 cm-1 (Figure 5.1). TGA data indicated that the corona 
of the AuNP is composed of 35% of azide ligands (Figure 5.2) and thus these nanoparticles 
contain azide functionalities at a concentration of 0.745 µmol mg-1. Based on 1H NMR 
spectrum and TGA data, and assuming that the nanoparticles have a spherical shape and 
that their size is monodispersed, we can estimate a nanoparticle formula of Au1000(Me-
EG3-S)455(N3-EG4-S)245 (calculation reported in Experimental). 
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Figure 5.2 TGA of control Me-EG3-AuNP (solid line) and of N3-EG4-AuNP (dashed line). 
The effectiveness of our SPAAC-PAD approach is shown through the example of 
bioconjugation of the arginylglycylaspartic acid (RGD) peptide. This peptide was chosen 
because it has targeting relevance. It is well-known to be specifically recognized by the 
integrin αvβ3 receptor and can act as tumour and angiogenesis marker.42,43 
In Scheme 5.1 two potential routes are illustrated for bioconjugation of the azide-AuNP 
with the RGD peptide. The first approach (Route 1, Scheme 5.1), involves preparing a 
“naked” peptide consisting of a dibenzocyclooctyl (DBCO) moiety connected via a 
polyethylglycol (PEG) linker to the RGD tripeptide (hereafter named “DBCO”-RGD). 
After preparation PEG-containing RGD, DBCO was constructed to the peptide via 
standard peptide coupling reaction. The resulting peptide, “DBCO”-RGD, was cleaved 
from the resin and deprotected by using 95/5 TFA/TES. After purification, it was then 
directly reacted with the azide-AuNP. The second approach (Route 2, Scheme 5.1) applies 
a construct possessing a side-chain protected peptide fragment (DBCO-(PG)RGD). It is 
noteworthy that dilute TFA (5/5/90 TFA/TES/DCM) was used as the reagent for cleavage 
of the peptide from the resin and for retention of protecting groups on peptide side chains. 
8 
 
The peptide reacted with the azide-AuNPs via an I-SPAAC and all protecting groups were 
removed in a post-assembly deprotection step. 
 
Scheme 5.1 Illustration of the attempted routes for the bioconjugation of azide-AuNPs with 
RGD peptide via SPAAC-PAD. (a) Use of an unprotected peptide (route 1) or use of a 
protected peptide (route 2), (b) and (c) molecular structures of “DBCO”-RGD and DBCO-
(PG)RGD. Protecting groups (PG) are Pbf and tBu. 
To undertake the approach described by Route 1, RGD peptide was synthesized via 
standard SPPS procedure using rink amide resin as the solid support (Scheme 5.2) and 
DBCO acid was coupled to N-terminus of the peptide. Cleavage from the resin and 
protecting group removal was done in one step by treatment with 95/5 TFA/TES. The 
resulting native peptide was purified by HPLC and characterized by ESI-MS. The observed 
molecular mass of 849.3472 was in agreement with the calculated mass (849.3657). In 
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spite of this, close examination of the UV-spectrum of the peptide indicated that the 
chromophore was changed from DBCO thus implying decomposition of DBCO had 
occurred (supplementary information). 
 
Scheme 5.2 Synthesis of DBCO-RGD peptide. 
A control experiment was carried out to determine if the standard Fmoc-based 
oligomerization chemistry cleavage condition of concentrated TFA induced decomposition 
of DBCO. Starting with DBCO amine, we measured its purity by HPLC before and after 
treatment with 95% TFA/DCM (rt, 1 hr). HPLC-UV absorption spectroscopy of the 
reaction mixture, along with subsequent 1H NMR and high resolution mass spectral 
analysis, clearly showed the complete consumption of starting material and the production 
of several products (Figure 5.3 and Figure 5.4). The two major components of the mixture, 
i.e. the peaks with retention time of 20-20.5 min and of 26-26.5 min do not correspond to 
DBCO. On-line monitoring showed significant changes the UV spectrum indicating 
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structural changes in the chromophore. The 1H NMR spectra of the two isolated 
compounds confirmed neither was DBCO (supplementary information). Mass spectral 
analysis showed that the earlier eluting peak retained the same mass as DBCO implying a 
molecular rearrangement had occurred, 31 while the later eluting peak possessed a greater 
mass. It's also noteworthy that the UV absorption spectrum of the first peak in Figure 5.4 
showed strong absorbance at 344 nm, which has also been detected in UV spectrum of 
“DBCO”-RGD, indicating that DBCO on peptide RGD had decomposed under the 
standard cleavage condition of 95% TFA. To study the stability of the DBCO moiety 
toward TFA, DBCO was exposed to a series of solutions of 0-50% TFA/DCM for 1 h at 
room temperature. Under these conditions, DBCO was found to be stable when the TFA 
concentration was less than 30%. 
 
Figure 5.3 HPLC-UV absorption analysis at 265 nm of DBCO amine. 
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Figure 5.4 HPLC-UV absorption analysis at 265 nm of decomposition of DBCO after 
treatment with concentrated TFA. 
Another control experiment was performed to model the interfacial SPAAC reaction by 
using “DBCO”-RGD peptide with an azide, namely ω-azido-triethylene glycol-
monomethyl ether (Me-EG3-N3) as the reactive partner. The reactions were carried out in 
either water or acetonitrile solutions and the course of the reaction was monitored by 
UPLC/ESI-MS. Only the two starting materials were detected over 4 hours, indicating that 
the “DBCO”-RGD peptide and Me-EG3-N3 were not undergoing the SPAAC. 
Independently it was determined that the Me-EG3-N3 was capable of participating in 
SPAAC with DBCO. Therefore, “DBCO”-RGD lost the ability of click and cannot be used 
as clickable peptide for bioconjugation of AuNPs. As a control for further study, the 
peptide “DBCO”-RGD was still added into azide-AuNPs (azide group:peptide, 1 : 1.2 
ratio). The mixture was stirred in water at room temperature for 1 h. After removal of 
solvent, AuNPs were purified by centrifugal filtration (Millipore centrifugal filter units 
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MWCO 10 kDa). As expected, characterization of these AuNPs by IR spectroscopy 
showed the absorption of the azide group at 2110 cm-1 was still present with similar 
intensity to the starting material, which indicated lack of SPAAC reactivity, and showed 
no stretching at 1685 cm-1 corresponding to the amide functional groups.  
To circumvent the problem of decomposition of DBCO, Route 2 was devised. First we 
prepared DBCO-(PG)RGD by using a mild cleavage condition and it was then clicked to 
the azide-AuNP and subsequently the peptide was deprotected (Scheme 5.1). To synthesize 
the DBCO-(PG)RGD, the acid sensitive 2-chlorotritylchloride resin was used as solid 
support. The synthesis of DBCO-containing peptide followed the above procedure, except 
that the cleavage was performed with TFA/TES/DCM (5/5/90). This treatment effected the 
cleavage of the peptide from the resin but left the protecting groups intact and did not 
destroy DBCO (Scheme 5.3). The resulting protected peptide was purified by HPLC and 
characterized by ESI-MS. The UV spectrum of DBCO-(PG)RGD showed the agreement 
with DBCO with absorbance at 290 nm and 308 nm. A model click was carried out with 
DBCO-(PG)RGD and Me-EG3-N3 in acetonitrile. Characterization of the reaction by 
UPLC/ESI-MS showed successful click, indicating that DBCO was not destroyed in the 
cleavage step. Then SPAAC between azide-AuNPs and DBCO-(PG)RGD was simply 
performed by adding them (azide:peptide, 1 : 1.2) in acetonitrile and stirring the resultant 
mixture at room temperature for 1 h (Figure 5.5). After reaction, the AuNPs were purified 
by using centrifugal filtration (Millipore centrifugal filter units MWCO 10 kDa) and 
washed with 60% MeOH/H2O until no unreacted peptide was observed in the UPLC/ESI-
MS analysis of the filtrate. The unreacted peptide was recovered from the filtrate and 
washings and the amount indicates that approximately 31% of the azide groups on AuNPs 
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had reacted. Therefore, the approximate nanoparticle formula can be calculated as 
Au1000((PG)RGD-linker-S)75(N3-EG4-S)170(MeEG3S)450. The IR spectrum of the purified 
(PG) RGD-AuNPs showed that the azide stretching mode at 2110 cm-1 had markedly 
decreased while it had not changed in Route 1 (Figure 5.6). Additionally, concomitant with 
the azide disappearance the appearance of stretching at 1685 cm-1 corresponding to the 
amide functional groups was observed, indicating that the protected peptide was covalently 
bonded to the AuNP via SPAAC. 
 
Scheme 5.3 Synthesis of DBCO-(PG)RGD peptide. 
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Figure 5.5 IR spectrum of PG-RGD-AuNPs. 
 
Figure 5.6 IR spectrum of RGD-AuNPs. 
15 
 
 
Figure 5.7 Bioconjugation of AuNPs with RGD peptide via SPAAC-PAD, 1) acetonitrile, 
room temperature, 1 h; 2) 90% TFA/DCM, room temperature, overnight; and AuNP size 
distributions obtained from the corresponding TEM image of RGD-functionalized AuNPs 
via SPAAC-PAD. 
To remove the protecting groups of the peptide, the AuNPs were then treated with 90% 
TFA/DCM at room temperature overnight to ensure complete deprotection. It is important 
to note that these small oligo-ethylene glycol-based AuNP are perfectly stable under these 
acidic conditions. TEM images recorded before and after this acidic treatment confirmed 
that the relatively harsh condition for PAD did not adversely affect the AuNP size 
distribution (Figure 5.7). The obtained RGD-AuNPs were then purified by dialysis using 
cellulose ester dialysis membranes (6-8 KDa MWCO). 
To further confirm that the interfacial SPAAC reaction had proceeded, the deprotected 
RGD-AuNPs were reacted with molecular iodine. Oxidation of AuNPs with iodine 
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dissolved the gold into a mixture of Au(I) and Au(III) complexes and released the corona 
ligands as disulphides.44 The structure of the most possible disulphide molecule produced 
by this reaction is shown in Figure 5.8. The mixture of disulphides was characterized by 
ESI-MS and the mass 1365.6084 [M+H]+ m/z agrees well with the calculated mass of 
1364.5992 for the proposed disulphide 1. Importantly the mass for the corresponding 
disulphide with the protected peptide was not observed, indicating that the complete 
deprotection was achieved. This confirms the successful bioconjugation of AuNPs with a 
short oligopeptide via SPAAC-PAD without interference with side chains of the peptide. 
Moreover, efficient substitution was achieved on the surface of small size AuNPs with 31% 
of the azide groups reacting with the RGD peptide. This result is comparable with the 
reported conjugation of AuNPs with peptides via covalent bonding,20 with the difference 
that this AuNP-bioconjugate was obtained through a simple and rapid pour-and-mix 
chemistry under ambient temperature and atmosphere while the purification only involved 
centrifugation and dialysis. The final calculated molecular raw formula of this AuNP is 
Au1000(RGD- linker-S)75(N3-EG4-S)170(MeEG3S)450. 
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Figure 5.8 Oxidative degradation of RGD-AuNPs by iodine. Disulfide 1 was characterized 
by ESI-MS. Calculated 1364.5992 and found 1365.6084 [1+] m/z. 
To test the versatility of this method we employed a peptide with different nucleophilic 
residues. In particular, because it has been reported that in presence of reduced 
peptidylcysteine residues, strained cyclooctynes mainly react via thiol-yne addition instead 
of SPAAC reaction, 33 we decided to synthesize a CRGDK peptide and conjugate it to the 
azide-AuNPs via our SPAAC-PAD strategy (Scheme 5.4). This peptide has an additional 
interest because it is a neuropilin-1 (Nrp-1) receptor-targeted peptide for cancer 
treatment.32,45,46 
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Scheme 5.4 Synthesis of DBCO-(PG)CRGDK peptide. 
For these experiments, we followed the same procedure as previously discussed with the 
noted exception. The CRGDK peptide was synthesized via standard Fmoc SPPS method 
and DBCO acid was coupled to the N-terminus. A change in the acid strength for resin 
cleavage (0.5% TFA/DCM) was made to preserve the trityl thioether protecting group of 
cysteine. After SPAAC-PAD, the CRGDK-functionalized AuNPs were characterized by 
IR (Figure 5.9). The azide stretch in the IR spectrum became weaker compared to the azide-
AuNPs before conjugation and the stretching at 1685 cm-1 corresponded to the functional 
groups of peptide bond appeared, suggesting successful conjugation through the I-SPAAC-
PAD. Also, a new absorbance at 2692 cm-1 indicated the existence of the thiol group of 
cysteine and shows that the side chain of cysteine that would otherwise react with 
cyclootyne via thiol-yne addition did not interfere with the I-SPAAC reaction with the aid 
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of PAD. Decomposition of the AuNPs by treatment with excess I2 followed by ESI-MS 
analysis showed the two most possible disulfide molecules expected after a successful I-
SPAAC-PAD, and no trace of protected peptide was found (Scheme 5.5). Therefore, our 
strategy showed to be also effective in creating small AuNP-oligopeptide bioconjugates in 
presence of nucleophilic residues that could otherwise attack the strained alkyne bond. 
 
Figure 5.9 IR spectrum of CRGDK-AuNPs. 
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Scheme 5.5 Oxidative decomposition of CRGDK-AuNPs by iodine. Disulfides 2A and 2B 
was characterized by ESI-MS. 2A calculated 1600.6645 and found 800.2318 [M+2H]2+. 
2B calculated 1242.5162 and found 621.6824 [M+2H]2+. 
Preliminary in vivo CT imaging of mice with brain and leg tumor, respective, have been 
performed by using RGD-functinalized AuNPs as the CA. The results showed that AuNPs 
were diffused within 3 minutes throughout the body without detectable contrast at the site 
of tumor, although contrast was detected in the bladder. This issue may be addressed by 
enlarging the size of AuNPs for the further improvements of CT images. 
5.3 Conclusion  
In summary, we have created a new, efficient, easy method to implement general approach 
to the synthesis of AuNP-peptide bioconjugates that combines the I-SPAAC reaction with 
post assembly deprotection. Using this strategy, peptides with protected side chains can be 
conjugated onto gold nanoparticles via I-SPAAC and all protecting groups can then be 
easily removed by PAD. The mild reaction conditions preserve the integrity of the alkyne 
so that it may perform the SPAAC reaction and the conjugated AuNPs are sufficiently 
robust to undergo peptide deprotection without deleterious effects. The approach presented 
herein usefully expands the repertoire of existing methods and presents an easy, reliable 
and quick way to functionalize AuNPs with short oligopeptides where the extent of 
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incorporation of the interfacial biomolecule can be easily quantified. We anticipate that the 
demonstrated methodology for peptide-AuNP bioconjugation via the SPAAC-PAD will 
enable the fabrication of gold nanoparticles with a high degree of complexity with 
biomolecules for a variety of applications in targeted cancer diagnosis and therapies. 
Further modification and functionalization of AuNPs for better results of targeted CT 
imaging is currently underway. 
5.4 Experimental  
Synthesis of “DBCO”-RGD peptide 
The “DBCO”-RGD peptide was synthesized manually via standard Fmoc SPPS procedure 
by using rink amide MBHA resin as solid support. Briefly, the peptide chain including 
RGD and a linker was grown on the resin and DBCO acid was coupled to terminate the 
peptide. The coupling of each residue used 5 equiv. (relative to the loading of resin) Fmoc-
protected amino acids, 5 equiv. of HBTU and 10 equiv. of DIPEA in a DMF solution for 
4 hours. During the synthesis, Fmoc protecting group was deprotected using 20% 
piperidine/DMF (v/v) for 15 minutes. At the end of the synthesis, DBCO acid was 
conjugated to the peptide following the above-mentioned procedure except that 1.1 equiv. 
DBCO acid, 1.1 equiv. HBTU and 2.2 equiv. DIPEA were used. After the completion of 
the synthesis, the resin was washed with DMF and DCM (each for four times) and dried 
under vacuum for 24 hours. Cleavage of the expected peptide and the removal of side chain 
protecting groups from the dried resin were performed by suspending the resin in cleavage 
cocktail containing TFA (95%) and TES (5%) for 1 hour. The filtration was concentrated 
to a viscous solution by flushing N2. After the precipitation in ice cold ether, the crude 
product was collected, dissolved in MQ water and freeze-dried. The characterization of 
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“DBCO”-RGD peptide with calculated mass 849.3657 [M+H]+ was performed by Waters 
LCT Premier ESI-MS and found 849.3395 [M+H]+. Purity: 98.7% determined by HPLC 
with a C18 column and using a linear gradient of acetonitrile and MQ water containing 
0.05% TFA. 
Synthesis of DBCO-(PG)RGD peptide 
The DBCO-(PG)RGD peptide was synthesized manually via standard Fmoc SPPS 
procedure by using 2-chlorotrityl chloride resin as solid support. The coupling of the first 
residue used 1.5 equiv. Fmoc-protected amino acid and 4 equiv. of DIPEA in a DCM 
solution for 2 hours. Other amino acid couplings and DBCO acid coupling were carried 
out followed by the above-mentioned procedure. Cleavage of the protected peptide from 
the dried resin was performed by suspending the resin in cleavage cocktail containing TFA 
(5%), TES (5%) and DCM (90%) for 1 hour. The filtration was concentrated to a viscous 
solution by flushing N2. The crude product was dissolved in acetonitrile and purified by 
HPLC. The characterization of DBCO-(PG)RGD peptide with calculated mass 1259.5784 
[M+H]+ was performed by ESI-MS and found 1260.5776 [M+H]+. Purity: 96.5% 
determined by HPLC with a C18 column and using a linear gradient of acetonitrile and 
MQ water containing 0.05% TFA. 
Synthesis of DBCO-(PG)CRGDK 
The synthesis was performed as described for DBCO-(PG)RGD. Cleavage of the protected 
peptide was performed by suspending the resin in cocktail containing 0.5% TFA/DCM for 
15 min. The filtration was concentrated to a viscous solution by flushing N2. The crude 
product was dissolved in acetonitrile and purified by HPLC. The characterization of 
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DBCO-(PG)CRGDK with calculated mass 1659.7393 [M+H]+ was performed by ESI-MS 
and found 1660.6294 [M+H]+. Purity: 94.8% determined by HPLC with a C18 column and 
using a linear gradient of acetonitrile and MQ water containing 0.05% TFA. 
Synthesis of azide AuNPs 
In a typical synthesis, 50.0 mg of Me-EG3-AuNP were transferred into a clean 25 mL round 
bottom flask. This compound was dissolved in 10 mL of acetone. Then 10.0 mg (42.5 µmol) 
of N3-EG4-AuNP were transferred into this solution. The reaction was stirred vigorously 
for 20 min. After this time, the acetone was immediately evaporated off. The thin film of 
nanoparticles was washed first with hexanes (in which AuNP are not soluble) and the 
solvent was removed under vacuum. Subsequently the film was quickly rinsed with 
isopropanol three times. This entire washing procedure was repeated three times until the 
odour of the thiol was gone. 44.9 mg of nanoparticles were obtained. The nanoparticles 
were dissolved readily in H2O, acetone, acetonitrile, methanol, ethanol, DMF, DMSO and 
DCM with little to no aggregation and characterized by 1H NMR and IR. 1H NMR (CD3CN, 
400 MHz): δH (ppm): 3.60, 3.49, 3.39, 3.31. 1H NMR (D2O, 400 MHz): δH (ppm):3.66, 
3.57, 3.43, 3.32. IR (KBr disk, cm-1): 2921, 2871, 2101, 1443, 1349, 1292, 1244, 1198, 
1119, 1033. 
Bioconjugation of azide AuNPs with RGD peptide via SPAAC-PAD 
DBCO-(PG)RGD (1.2 equiv. of DBCO relative to azide substitution on AuNPs) and azide 
AuNPs were mixed in 3 mL acetonitrile at room temperature for 1 hour. After that, the 
AuNPs were purified by using centrifugal filter devices (10KDa MWCO) and washed with 
60% MeOH/H2O until no unreacted peptide can be found be ESI-MS. The resulting AuNPs 
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were treated with 90% TFA/DCM at room temperature overnight and the solvent removed 
by flushing N2. The obtained AuNP-RGD were purified by dialysis against water using 
Cellulose ester dialysis membranes MWCO of 10 kDa for 2 days and characterized by IR, 
TEM and ESI-MS. IR (KBr disk, cm-1): 3370, 2930, 2110, 1685, 1109. 
Bioconjugation of azide AuNPs with DBCO-(PG)CRGDK 
The bioconjugation was performed as described for AuNP-RGD. The obtained AuNP-
CRGDK after SPAAC-PAD was characterized by IR and ESI-MS. IR (KBr disk, cm-1): 
3370, 2930, 2692, 2110, 1685, 1446, 1346, 1109. 
Calculation of nanoparticle formula 
Assuming that the AuNPs are spherical and that their size is monodisperse (3 nm) it is 
possible to calculate an approximate molecular formula for azide AuNPs. The number of 
gold atoms (NAu) can be calculated using the following formula: 
 =

6
 
Where ρ is the density of the face centered cubic (fcc) gold lattice (19.3 g⋅cm-3), d is the 
average diameter of the nanoparticles in centimeters found from the TEM images, MAu is 
the mole atomic weight of gold (196.9665 g mol-1), and NA is Avogadro constant. 
The number of thiol ligands surrounding the gold core (NL) can be calculated using the 
following formula: 
 =
!%
(1 −!%)[!%&'()*'+%  [!,-'()&'+(1 −!%)]]
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Where W% is the percentage of mass loss due to the organic ligands found through TGA 
measurements, MWMe-EG3-S is the molecular weight of the thiolate ligand, MWN3-EG4-S is 
the molecular weight of the azide thiolates ligand, and M% is the mole percentage of azide 
ligand. 
5.5 Supplementary Information 
 
Figure 5.10 ESI-MS analysis of “DBCO”-RGD. Calculated mass 849.3657 [M+H]+ and 
found mass 849.3472 [M+H]+. 
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Figure 5.11 ESI-MS analysis of DBCO-(PG)RGD. Calculated mass 1259.5784 [M+H]+ 
and found mass 1260.5776 [M+H]+. 
 
Figure 5.12 ESI-MS analysis of DBCO-(PG)CRGDK. Calculated mass 1659.7393 
[M+H]+ and found mass 1660.6294 [M+H]+. 
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Figure 5.13 ESI-MS analysis of disulfide 1 from re-oxidation of AuNP-RGD by iodine. 
Calculated mass is 1364.5992 and found mass is 1365.6084 [M+H]+ for Disulfide 1. 
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Figure 5.14 ESI-MS analysis of disulfide 2A (top) and 2B (bottom) from re-oxidation of 
AuNP-CRGDK by iodine. Calculated mass is 1600.6645 and found mass 800.2318 
[M+2H]2+ for 2A.  Calculated mass is 1242.5162 and found mass 621.6824 [M+2H]2+ for 
2B. 
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Figure 5.15 HPLC-UV absorption analysis at 265 nm of “DBCO”-RGD. 
 
Figure 5.16 HPLC-UV absorption analysis at 265 nm of DBCO-(PG)RGD. 
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Figure 5.17 HPLC-UV absorption analysis at 265 nm of DBCO-(PG)CRGDK. 
 
 
Figure 5.18 1H NMR spectrum of azide AuNP recorded in acetonitrile-d3 and calibrated 
against residual acetonitrile (*). 
31 
 
 
Figure 5.19 TGA of control Me-EG3-AuNP (solid line) and of N3-EG4-AuNP (dashed line). 
 
Figure 5.20 TEM image of azide AuNPs. 
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Figure 5.21 TEM image of RGD-AuNPs. 
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Figure 5.22 1H NMR (top) and ESI-MS (bottom) spectra of DBCO amine (found mass: 
278.1120 [1+]).  1H NMR Spectra were recorded in CDCl3. 
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Figure 5.23 1H NMR (top) and ESI-MS (bottom) spectra of isolated compound (found 
mass: 278.3239 [1+]).  1H NMR Spectra were recorded in D2O/ACN-d3 (2:1). 
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Figure 5.24 1H NMR (top) and ESI-MS (bottom) spectra of isolated compound (found 
mass: 302.0555 [1+]) after treatment of DBCO amine with concentrated TFA. 1H NMR 
Spectra were recorded in CDCl3. 
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Figure 5.25 IR spectrum of DBCO-PG-RGD. 
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16. CHAPTER VI: ONCLUSION AND OUTLOOK 
With superior hybridization features, resistance to nucleases and proteases, chemical 
robustness and excellent sequence discrimination, PNA has become one of the most 
attractive artificial nucleic acids. PNA has demonstrated its utility as hybridization probes 
for molecular diagnostics, potential for antisense/antigene therapy as well as targeted 
imaging. However, the difficulties in preparing modified PNA probes remain in PNA 
chemistry, because it is usually expensive, time-consuming and labor-intensive to 
functionalize PNA. In order to prepare desired PNAs more efficiently and cost-effective, 
methodologies for the functionalization of PNA via post-synthetic click chemistry has been 
explored and discussed in this thesis. The developed approaches are convenient, simple 
and versatile, and provided a route to diverse PNA probes that have been evaluated. 
Chapter II introduced the synthesis of quencher-free PNA molecular beacons by a 
simultaneous attachment of fluorophores via on-resin CuAAC for the first time. This easy, 
flexible method showed variability in development of single- or multiple-labeled PNAs. 
The pyrene-based stem-loop PNA beacon has shown its promise in the detection of cystic 
fibrosis genes and obviously could be extended to many target sequences or fluorophores. 
Chapter III presented the development of conventional PNA molecular beacons via a 
"click-couple-click" strategy. A quencher and a fluorophore can be attached to a PNA 
oligomer sequentially without the need of complicated protection and deprotection of 
reactive sites of PNA. Microwave-assisted on-resin CuAAC has been applied for the first 
time to PNA, to the best of my knowledge, and the procedure of "click-couple-click" 
approach is fast, robust, efficient and operationally simple. Given that PNA probes are still 
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difficult and very expensive to be obtained, the presented method in this chapter will be of 
great help in rapidly and easily synthesizing various PNAs. A series of PNA beacons have 
been successfully synthesized and characterized. This methodology complements the one 
presented in Chapter II for the synthesis of homo-dimer MBs. Thus, this method gives 
more synthetic variability in the choice of fluorophore-quencher or donor-acceptor pairs 
for customized MB construction. 
Expanding on the aforementioned click chemistry, Chapter IV showed the preparation of 
a Gd(III)-containing PNA hybridization probe as a potential MRI contrast agent. Four units 
of alkynyl Gd(III)-DOTA were clicked to a PNA simultaneously and the resulting oligomer 
has been demonstrated useful in binding with the poly(rA) tail. This method significantly 
simplify the procedure for the conjugation of a PNA probe with Gd chelators which 
generally requires coupling of chelators like DOTA, protection and/or deprotection of 
nucleobases as well as Gd chelation. By bindng to poly(rA) to form a triplex, the probe, 
(Gd(III)-DOTA)4-PNA, would concentrate and deliver a high load of Gd ions in a 
microenvironment.  
As AuNPs are promising CT contrast agents, bioconjugation of PNAs to AuNPs for 
targeted CT imaging would also be of great interest. The use of a peptide would be a good 
start for investigation of the conjugation methods. In chapter V, peptide-decorated AuNPs 
via strain-promoted azide-alkyne cycloaddition and post assembly deprotection (SPAAC-
PAD) is presented. SPAAC was applied for the bioconjugation of AuNPs because of the 
benefits of copper-free click chemistry. Due to the possible decomposition of cyclooctyne 
under regular conditions for peptide cleavage, post assembly deprotection has been 
proposed and proven to be helpful for the conjugation. This method has been demonstrated 
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useful and convenient for functionalization of small, water-soluble gold nanoparticles with 
oligopeptides. Future studies on decoration of AuNPs with PNAs by using SPAAC-PAD 
should be performed.  
To expand the application of PNA and thoroughly investigate the properties of PNA probes, 
synthetic protocols which are more cost-effective, robust, convenient and versatile for are 
needed. Therefore, with the chemistry and procedure developed during this thesis, rapid 
preparation of various PNA probes is made possible, which may reduce the difficulties in 
functionalization of PNAs as performed in research laboratories and commercial 
companies.  
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